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ABSTRACT 
Clark, Reilly June, Ph. D., Biomedical Sciences, Wright State University. 2019. Differential 
microRNA expression in Barrett’s Esophagus Correlates with Regulation of Posterior HOX 
Genes. 
Barrett’s Esophagus (BE) is characterized by the appearance of an intestinal-like epithelium in 
the distal esophagus. The molecular mechanisms behind BE development are unknown. BE is 
often preceded by Gastroesophageal Reflux Disease (GERD) and predisposes patients to 
esophageal adenocarcinoma (EAC). Due to the high mortality rate associated with EAC, BE 
patients are continuously monitored through upper endoscopy with biopsy for progression to low 
grade dysplasia (LGD), high grade dysplasia, and EAC. This monitoring technique poses 
numerous risks, so alternative surveillance and diagnostic techniques for BE pathogenesis are 
continually studied. microRNA biomarkers in BE pathogenesis may provide alternative means of 
diagnosis as well as a greater understanding of BE and its progression to EAC. Here, small RNA-
sequencing of serum and tissue from GERD, BE, LGD, and EAC patients revealed three 
candidate tissue microRNAs differentially expressed in BE compared to GERD patients. 
Differential expression of the three candidate microRNAs was validated in a second cohort of 
BE and GERD patient tissues by quantitative PCR. Gene target analysis revealed two candidate 
microRNAs are homeobox (HOX) microRNAs, which directly target central and posterior HOX 
genes. HOX genes are transcription factors which regulate gene expression along the anterior/
posterior axis. BE resembles a homeotic transformation, which could be due to aberrant 
expression of posterior HOX genes in the esophagus, an anterior organ. The third candidate 
microRNA targets a component of Polycomb Repressive Complex 1, a transcriptional repressor 
of HOX genes. Thus, the three candidate microRNAs may modulate posterior HOX gene 
expression associated with BE development. 
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INTRODUCTION 
Barrett’s Esophagus (BE) 
The esophagus serves as an intermediary organ in the human gastrointestinal system 
between the oral cavity and the stomach. Unlike either of these organs, the esophagus 
does not play a role in digestion or absorption of nutrients. In a normal human adult, the 
entire esophagus is lined with a stratified squamous epithelium [1]. Several pathological 
conditions of the esophagus exist including esophagitis, esophageal squamous cell 
carcinoma, gastroesophageal reflux disease (GERD), Barrett’s Esophagus (BE), and 
Esophageal Adenocarcinoma (EAC) [2, 3]. The three latter conditions are thought to be 
linked.  
GERD describes a chronic disorder in which gastric juice is refluxed past the lower 
esophageal sphincter into the distal esophagus. GERD patients experience continual pain 
and inflammation due to the chronic exposure of the esophageal epithelium to the acidic 
refluxate [4, 5]. The incidence of GERD has been on the rise in the United States [6]. 
Obesity can be a precursor condition to GERD. Rising rates of adult obesity in the United 
States are thought to be a contributing factor to GERD’s increased incidence [7]. 
However, the causes of GERD are varied and cannot always be linked to higher BMI [4]. 
Hiatal hernias and structural abnormalities in the esophageal sphincter are also associated 
with this chronic disorder [8].  
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In BE, regions of normal squamous epithelium are replaced by a simple columnar 
epithelium interspersed with intestinal-type cells, termed intestinal metaplasia [9]. BE is 
most associated with the presence of goblet cells in the distal esophagus, a typical cell 
type in the small intestinal epithelium [10, 11]. A BE diagnosis is frequently preceded by 
GERD [6, 12-14]. BE lesions do not present any additional symptoms, and there are no 
treatments to reverse or prevent BE. The only recourse following a BE diagnosis are 
antacids and proton pump inhibitors to increase the pH of the refluxate, mediating the 
pain and inflammation characteristic of GERD [15]. Several studies have shown the 
acidic environment created by gastric reflux can alter epithelial cell signaling [16, 17]. 
Introduction of bile acids from the small intestine through duodenal esophageal reflux 
can promote intestinal-type gene expression in the esophageal epithelium, most notably 
caudal-related homeobox 2 (CDX2) and acid mucin 2 (MUC2) [18]. It is still unclear 
whether the intestinal-type signaling promoted by acid reflux is the initiating event of BE 
development or a later event following replacement of the normal squamous epithelia.  
A BE diagnosis does significantly increase patient risk for Esophageal Adenocarcinoma 
(EAC). A risk evaluation by Cameron et al (1985) has shown that a BE patient’s risk for 
EAC can reach 100 fold that of a patient without BE [19]. EAC diagnoses comprise less 
than 1% of all cancer diagnoses every year in the United States [11, 20][11, 20][11, 
20][11, 20]. Yet, EAC mortality rate has been reported as high as 80% [21]. EAC tumors 
are difficult to diagnose in their early stages, as the epithelium of the distal esophagus is 
impossible to self-monitor. Unless EAC is caught early enough to enable ablation or 
surgical resection of the tumor, the five year survival rate is less than 5% [21]. Surgical 
resection is the most successful treatment available for this cancer.  Smoking and alcohol 
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consumption are minor risk factors for EAC, but the only known major risk factor for 
EAC is BE [22]. EAC tumors have been shown to originate from BE lesions [23]. BE 
pathogenesis follows a sequence: GERD, BE, BE with low grade dysplasia, BE with high 
grade dysplasia, and finally EAC. Both the American Gastroenterological Association 
(AGA) and the American College of Gastroenterology (ACG) recommend that GERD 
and BE patients are monitored every 3-5 years for signs of BE lesions, dysplasia, and 
EAC [10, 20]. Upon detection of dysplastic or cancerous tissue, the affected tissues are 
either removed or subjected to more frequent monitoring. BE lesions without dysplastic 
characteristics can remain benign for decades. It is estimated that only 0.2-2.1% of BE 
patients progress to dysplasia or EAC every year [24].  Since it is not yet possible to 
predict which BE patients will develop EAC, a BE diagnosis in a GERD patient does not 
affect the AGA/ACG- recommended monitoring regimen.  
Models for BE Development 
Hypotheses abound concerning the origin of BE lesions [25]. Three major hypotheses 
have been explored in the literature pertaining to BE development: transdifferentiation of 
resident squamous epithelial stem cells, emergence of residual embryonic stem cells, and 
migration of stem cells from a distinct location.  
Transdifferentiation 
In terms of the number of peer-reviewed studies, the “transdifferentiation” hypothesis for 
BE development has been the most popular. This hypothesis posits that the squamous 
epithelial stem cells of the distal esophagus transdifferentiate upon some stimulus into 
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columnar epithelia cells to form BE lesions  [26, 27]. In other tissues, it has been shown 
that adult stem cells can transdifferentiate into other cell types [28, 29]. One study offers 
an apparent intermediate stage in BE transdifferentiation, in which an epithelial cell had 
markers of both squamous and columnar epithelia [30]. Alternately, Jiang et al (2017) 
identified a transitional epithelium in the distal esophagus which contained a squamous–
columnar junction basal cell population [31]. Upon exposure to CDX2, these cells can 
differentiate into intestinal-type cells. In the small intestine, columnar epithelia 
transdifferentiate into goblet cells and other intestinal-type cells through the actions of 
CDX1 and CDX2 [32]. CDX gene expression in the adult esophageal epithelium is a 
well-validated marker of intestinal metaplasia [33-35]. In BE, CDX1 is known to 
upregulate markers of epithelial differentiation, including cytokeratin 20 and villin [36]. 
Intestinal metaplasia in BE is positive for CDX2, MUC2, and villin expression [37]. 
CDX1 also targets effectors of Wnt, Retinoic Acid, and Fibroblast Growth Factor (FGF) 
signaling [38-40]. CDX1 expression can induce transdifferentiation of esophageal 
keratinocyte cell lines to a cell type which stains positive for acid mucins by Alcian Blue 
staining [41]. It is therefore possible that CDX1 and CDX2 expression in BE results in 
transdifferentiation of cells within an existing simple columnar epithelium to goblet cells 
and other intestinal-type cells. However, the molecular signaling events that would lead 
to squamous epithelial transdifferentiation have not been revealed.  
Several studies have investigated the initiating factors which may prompt 
transdifferentiation in BE, including bile acids and retinoic acid [18, 42, 43]. In a 2015 
study by Sun et al, bile acid treatment in a rat model can induce expression of markers of 
BE, including CDX2 and MUC2 in BE-like metaplastic lesions [42]. However, in that 
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study, the formation of the metaplasia was believed to result from the heightened 
inflammatory response in the esophagus upon bile acid treatment. While it has been 
shown that bile acids can be potent modulators of cell signaling, especially in a neutral 
pH refluxate, no evidence has been put forth that shows its role in BE transdifferentiation. 
In the embryonic esophagus, a simple columnar epithelium is differentiated into a 
stratified squamous epithelium [44].  In embryogenesis, such differentiation of epithelial 
stem cells is triggered by retinoic acid signaling [45]. Retinoic acid activity is increased 
in BE lesions, which may elucidate the increased expression of CDX genes in those same 
tissues [45]. CDX1 and CDX2 are downstream effectors of retinoic acid signaling [38, 
46, 47]. Together, this indicates some role of retinoic acid signaling in BE development.  
Residual embryonic cell populations 
Tumor protein p63 is responsible for maintenance of stratified epithelia [48]. It has been 
documented that BE tissues do not express p63, which distinguishes them from the 
normal esophageal squamous epithelium [49]. In p63-null mice, stratified squamous 
epithelial tissues are replaced by a simple columnar epithelium which resembles BE 
lesions [48, 49]. Since p63 is not necessary for differentiation of the squamous 
epithelium, a 2011 study by Wang et al contended that BE may not form from 
transdifferentiation, but instead a physical replacement of the squamous cells by a 
residual embryonic population of columnar epithelia [50]. In mouse embryonic 
development of the esophagus and proximal stomach, a simple columnar epithelia 
precedes the formation of the mature stratified squamous epithelium [51]. Also in the 
Wang 2011 study, both human BE and the esophagus of a p63-null mouse were observed 
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to exhibit similar expression of known BE biomarkers, including Keratins 8, 18, and 20, 
as well as Anterior gradient 2 (Agr2), Trefoil factors (TFF) 1-3, and Villin1 [50, 52, 53]. 
CDX2, a marker of the intestinal-type cells which occur in BE lesions, is not expressed in 
p63-null mouse esophagus [50]. Perhaps, expression of CDX2 expression in the distal 
esophagus, and thus the appearance of intestinal-type cells, is a separate event from the 
development of the simple columnar epithelium.  
Stem Cell Migrations 
The hypothesis that BE is the result of stem cell migration is also popular. The initial 
location of the migrating stem cells is a matter of much debate. Since BE was first 
described in the 1950s, there has been a number of studies investigating the idea that the 
stem cells maintaining these lesions originate in the gastric cardia, the region of the 
stomach immediately adjacent to the gastroesophageal junction[54-56]. The epithelium of 
the gastric cardia is columnar, resembling the columnar epithelia characteristic of BE 
[55]. Intestinal metaplasia does occur in the gastric cardia [57]. These lesions differ from 
BE, as they do not possess the same drastically increased risk of cancer [58].  
An alternate source for migrating BE stem cells are the esophageal submucosal glands. 
Intestinal metaplasia has been discovered in these glands and is referred to colloquially as 
buried metaplasia [59]. Some studies indicate that columnar epithelial cells are present in 
these submucosal glands and even share mutations with adjacent BE lesions [60]. 
Surveillance through upper endoscopy with biopsy can miss the lesions [61]. Therefore, it 
is currently unknown whether buried metaplasia is the source of BE lesions or simply an 
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extension of adjacent lesions. Alternatively, Garman and McCall argue that buried 
metaplasia may not be intestinal metaplasia but instead the result of acinar ductal 
metaplasia [25]. 
Sarosi et al (2008) hypothesized and showed in a rat reflux model that bone marrow 
derived cells found in the esophagus could be linked to formation of the intestinal 
metaplasia [62]. This study was performed in a rat esophageal reflux model, and 
formation of the intestinal metaplasia was observed after a bone marrow transplant. This 
hypothesis remains controversial, because its applicability to human BE patients with 
chronic acid reflux was not clearly established [17, 63]. 
While hypotheses concerning the cellular origin of BE abound in the literature, it has 
become obvious that the inability to observe BE development in vivo, either in an animal 
model or a 3-D human cell culture model has been a large roadblock in the field’s 
progress [64]. Thus, the drive for insight into the origin of BE has turned towards the 
differential signaling which occurs in each stage of BE pathogenesis [65]. Although each 
hypothesis discussed regarding the origin of BE has merit, there is much to be learned 
about these lesions. Our incomplete understanding of how BE develops and what induces 
its progression to dysplasia and EAC hinders our ability to appropriately diagnosis, treat, 
or prevent BE and EAC. Identifying pertinent signaling pathways and biomarkers for 
each stage of BE pathogenesis may aid in these processes [66]. 
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Homeotic Genes in BE Development 
BE lesions Resemble Homeotic Transformations 
Homeotic transformation refers to the development of structures in an inappropriate body 
region. The classic example occurs in Drosophila where a leg develops in the place of an 
antennae, a phenomenon known as antennapedia [67]. Several human gene disorders are 
attributed to homeotic transformations [68]. BE occurs in the esophagus, but it is 
characterized by the appearance of an epithelium resembling a more posterior portion of 
the gastrointestinal tract, the small intestine. BE developments in adulthood, rather than 
during embryonic development, but its resemblance to homeotic transformations is 
striking [9, 69]. Homeotic transformations are the result of dysregulated homeotic gene 
expression [70].  
Homeotic genes are transcription factors which contain a homeobox domain and 
determine segment identity along the anterior/posterior axis. The ANTP class, the largest 
class of homeotic genes, is only found in metazoans [71]. The name of this class is 
derived from Antennapedia gene in Drosophila. 255 ANTP-class homeotic genes are 
present in the human genome.  Many of these are in the HOX, ParaHOX, and Nyx gene 
clusters. Eight of the known human homeotic genes have been shown to be differentially 
regulated in BE tissues (Table 1). The HOX and ParaHOX gene clusters are heavily 
involved in the normal development of the human GI tract. These gene clusters are 
hypothesized to have originated from the same ancestral ProtoHOX gene clusters, based 
on the similarities in their homeobox domains [72].  
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Table 1: Human ANTP-class Homeotic Genes Differentially Regulated or Mutated in BE 
Pathogenesis 
Gene 
Symbol Gene Name Regulation/Mutation in BE Reference 
CDX1 caudal type homeobox 1 Upregulated [1] 
CDX2 caudal type homeobox 2 Upregulated [2-5] 
HOXB5 homeobox B5 Upregulated [6] 
HOXB6 homeobox B6 Upregulated [6] 
HOXB7 homeobox B7 Upregulated [6, 7] 
PDX1 pancreatic and duodenal 
homeobox 1 
Upregulated [8-10] 
BARX1 BARX homeobox 1 SNP1 [10-14] 
MSX1 msh homeobox 1 SNP1 [15] 
1 SNP: single nucleotide polymorphism 
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HOX genes regulate Positional Expression of Intestinal-type Genes 
Members of the HOX gene clusters are expressed throughout the body [72]. In 
embryogenesis, HOX genes are expressed in the mesoderm in a certain pattern which 
specifies each body segment, termed the HOX code [73]. As embryonic development 
progresses, HOX gene expression is initiated in the posterior regions of the body and 
spreads anteriorly [74]. This promotes “posterior prevalence” which endures past 
embryonic development and into adulthood. HOX genes are essential in the formation 
and specification of the three GI segments, the foregut, midgut, and hindgut, in 
embryonic development [75-77]. 
In bilateral metazoans, HOX gene spatial and temporal expression along the AP axis is 
essential in maintaining segmental identities [78]. As a result of genome duplications in 
human evolution, HOX genes occur in four clusters: HOXA, HOXB, HOXC, and HOXD 
[79, 80]. The expression of HOX genes in a cluster is collinear: the order of a HOX gene 
on the chromosome determines its positional expression in the body. Posterior HOX 
genes from the HOXB cluster have been shown to be upregulated in BE tissues (Table 1) 
[69]. 
HOX genes are regulated by protein complexes which modify chromatin structure. 
Polycomb Repressive Complexes (PRC) promote closed chromatin structure and repress 
HOX gene expression, while Multiple Lineage Leukemia (MLL) complexes promote 
open chromatin structure and activate HOX gene expression [81-84]. It is unknown how 
these complexes are recruited to the appropriate HOX genes to regulate gene patterning 
along the AP axis.  
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ParaHOX genes regulate posterior gut development as well as HOX gene expression 
The ParaHOX gene cluster includes PDX1, CDX1, CDX2 and CDX4 [72]. Expression of 
the ParaHOX genes are confined to the endoderm and regulate the expression of other 
homeotic genes in the gut along the AP axis [72]. CDX2 is the most posterior ParaHOX 
gene. All three CDX genes are expressed in the gut endoderm of the human embryo and 
have roles in gene expression patterning in posterior segments of the gut [85]. Together, 
these genes act as transcriptional activators for more than 3,000 genes [86]. They are 
significant players in the maturation, differentiation, and maintenance of the intestinal 
epithelium [86]. Both CDX1 and CDX2 are not expressed in the normal squamous 
epithelium of the distal esophagus, yet aberrant expression of both CDX genes has been 
widely documented in BE [17, 33-36, 87-89].  
In a CDX2-null mouse embryo, an apparent homeotic transformation occurs, wherein the 
intestine develops with a mucosa resembling the esophagus and proximal stomach 
instead of the mature differentiated epithelium [87]. In BE, CDX1 is known to upregulate 
markers of epithelial differentiation, including cytokeratin 20 and villin [90]. CDX1 also 
targets effectors of Wnt, Retinoic Acid, and Fibroblast Growth Factor (FGF) signaling 
[38-40]. CDX gene activity can be regulated by Wnt/B-catenin signaling and BMP4 
signaling, which are dysregulated in BE [91].  
In the small intestine, CDX1 and CDX2 regulate expression of the HOX genes [39]. 
Central genes from all four HOX gene clusters can be targeted directly by CDX2 [92]. 
HOXA genes have been found to be activated by CDX1. CDX1 binds to a CDX-binding 
site in the HOXA gene cluster and acetylates Histone H3 at Lysine 27, an activating 
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epigenetic mark [93]. CDX gene inactivation can affect central HOX gene expression, 
which can manifest as homeotic transformations in vertebral column [47].  
Protein Markers of BE 
BE tissue can be differentiated from normal esophageal tissue due to the presence of 
intestinal-type cells and associated molecular signaling. Numerous signaling pathways 
involved in inflammation, epithelial differentiation, and tumorigenesis are dysregulated 
in BE lesions [94]. Sonic Hedgehog, canonical Notch, and NF-κB signaling all appear to 
be dysregulated in BE tissues [95-99]. Intestinal-type proteins including various 
columnar cytokeratins, AGR2, TFF1-3, villin, the acid mucins, and CDX1 and CDX2 are 
aberrantly expressed in BE [37].  
Epithelial cytokeratins are the intermediate filaments types I and II composing the 
cytoskeleton of epithelial cells [100, 101]. Different subsets of cytokeratins (CK) are 
expressed by normal squamous epithelium and BE lesions [102].  The diversity of 
cytokeratin expression in epithelial tissues is thought to be linked not only to the 
epithelial cell type but also to the extent of differentiation in the tissue [100, 103]. 
Squamous epithelia express a larger subset including CK10, CK13m and CK14 [36, 51]. 
Since BE lesions are a heterogeneous collection of different cells, the subset of 
cytokeratins expressed can vary. CK7, CK8, CK18, CK19, and CK20 are all associated 
with BE tissues [36, 51, 102]. Cytokeratins are known to be differentially expressed in 
tumorigenic tissues and have been considered for serum biomarkers for various cancers 
[100].  
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Anterior gradient 2 (AGR2), Villin, and Trefoil Factors 1-3 (TFF1-3) are all proteins 
expressed in mucosal epithelium, such as the lining of the small intestine [65]. Like the 
columnar cytokeratins, villin is a cytoskeletal protein essential to form microvilli in the 
small intestine [104]. The trefoil factors are associated with mucins secreted by columnar 
epithelial and goblet cells in the small intestine [105]. All three proteins are highly 
upregulated in BE and EAC [104-107].  
The acid mucin, MUC2, is an excellent protein marker of BE lesions. Goblet cells, whose 
presence is required to diagnose BE, and other intestinal-type cells secrete mucins, 
including MUC2 [108]. Mucins are not normally expressed in the esophageal epithelium; 
however, their expression in BE lesions results in an adherent mucous barrier [109]. This 
barrier contains neutral mucins, acid mucins, sialomucins, and sulfomucins [110, 111]. 
The extent of expression and the types of mucins expressed vary among BE patients.  The 
expression of mucins is promoted by the abnormal expression of CDX2 in BE [89].  
Surveillance of BE Development and Progression to EAC 
Upper GI Endoscopy with Biopsy 
The gold standard for surveillance of BE pathogenesis is an upper gastrointestinal 
endoscopy with histological confirmation from biopsies [112, 113]. This invasive method 
to diagnose and monitor BE first requires visual examination of the distal esophagus. BE 
lesions possess a distinct color and texture compared to the normal esophageal 
epithelium. Upon locating BE lesions, puncture biopsies are obtained along the length of 
the lesion. In the standard Seattle protocol, biopsies are to be taken every 2 centimeters 
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[64]. The biopsies are examined for characteristics of BE as well as signs of dysplasia 
and cancer. A hematoxylin-eosin stain shows the presence of the simple columnar 
epithelium characteristic of BE, as well as signs of cancerous cells. Confirmation of BE is 
done through Period-Acid Schiff (PAS) staining combined with an Alcian Blue stain 
[58]. PAS stains neutral mucins, while Alcian Blue stains acid mucins. Acid mucins are 
secreted by goblet cells, the defining characteristic of BE lesions [114, 115]. Neutral 
mucins tend to be associated with the columnar epithelia [114]. While upper endoscopy 
with biopsy is the most effective tool available to monitor patients for BE pathogenesis, it 
poses risks to patients. Insertion of the endoscope into the esophagus can result in 
coughing and gagging [116]. The need for sedation to prevent gagging to safely complete 
the procedure is also a disadvantage to this method. Inflammation and esophageal tearing 
can occur, as well as infection at the biopsy sites [117, 118]. Patient anxiety is extremely 
common with these procedures and can prevent patient compliance to the suggested 
surveillance regimen.  
Dysplasia in BE lesions can be difficult to confirm histologically, as they rely on a 
pathologist’s interpretation of a small number of biopsies. Montgomery et al (2001) 
showed inflammation could obscure accurate diagnosis of a BE patient, even when the 
tissue was examined by multiple experts [119]. This is a critical problem for patients and 
clinicians. Early detection of dysplasia in BE patients is vital to diagnosing EAC in its 
earliest stages, when it can be ablated or surgically resected from the esophagus. False 
results from endoscopy with biopsy can lead to two undesirable scenarios. With a false 
negative diagnosis, a patient progressing to metastatic EAC could have necessary 
treatment delayed by months to years. In the case of a false positive diagnosis, a BE 
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patient without dysplasia would face unnecessary additional surveillance with its 
associated risks. The prevalence of false diagnoses in BE patients has been documented 
[120, 121].  The invasiveness and health risks posed by upper endoscopy with biopsy 
appear to far outweigh its sensitivity and specificity. The cost effectiveness of this 
method has been controversial.  
Alternative Surveillance Techniques 
Producing an alternative surveillance technique for BE and its pathogenesis with superior 
sensitivity, accuracy, and safety is a major clinical challenge. Several alternative 
surveillance techniques to monitor BE pathogenesis exist but are not currently included in 
AGA/ACG recommendations. These surveillance methods utilize visual examination of 
the esophagus, epithelial cell collection, and biomarker analysis. A 2017 review by 
Offman et al showed that many proposed alternative techniques explored rely on less 
invasive visual examination of the esophagus but still require a puncture biopsy for a 
confirmed BE diagnosis [116]. Cell collection methods such as the Cytosponge procedure 
provide less invasive means to collect cells from the distal esophagus for diagnosis 
confirmation [122]. Contamination by epithelia from the proximal esophagus and the oral 
cavity is a concern for these alternate methods. A balloon-based cell collection method 
described by Moinova et al (2018) circumvents this issue by protecting the sample inside 
a capsule before withdrawal from the distal esophagus [123]. The invasiveness of the 
original surveillance method is at least partially addressed by these alternatives. The 
sensitivity and specificity of these techniques for BE pathogenesis still relies upon 
histological analysis of the esophageal tissues or cells.  
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Alternative Diagnostic Techniques 
An alternative confirmation method is to probe for tissue biomarkers associated with each 
stage of BE pathogenesis. BE tissues can be differentiated from normal squamous 
epithelial tissues by the previously introduced protein markers of BE. However, it can be 
difficult to distinguish non-dysplastic BE from BE with dysplasia, since many of the 
same proteins are expressed yet the hallmarks of cancer observed in EAC are not present 
[124, 125]. 
Epigenetic biomarkers can differentiate BE tissues from normal squamous epithelia. 
Moinova et al found that DNA methylation at the vimentin and cyclin A1 loci could 
differentiate BE patients from non-BE patients [123]. Prior to that study, Kaz et al (2016) 
showed unique DNA methylation signatures between BE and EAC patients [126]. These 
biomarkers are associated with the simple columnar epithelia in BE, rather than the 
intestinal-type cells. The microRNAs are another set of promising epigenetic biomarkers 
for BE pathogenesis. Over 90 microRNAs have been found to be differentially expressed 
in BE and EAC when compared to normal squamous epithelia [94].  
An ideal technique to diagnose BE pathogenesis would be serum biomarker testing. 
Collection of patient blood is minimally invasive. Such testing requires a panel of serum 
biomarkers which can differentiate among the stages of BE pathogenesis. Serum 
metabolites can be used to differentiate BE from GERD and from BE with dysplasia 
[127]. EAC can be identified by hypermethylation at the adenomatous polyposis coli 
promoter regions [128]. In their exploratory study, Bus et al (2016) demonstrated that 
seven serum microRNAs are differentially expressed in BE and EAC [129]. This was 
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further supported by Chiam et al (2015) which identified serum microRNA signatures 
which could distinguish BE patients from EAC patients [130].  
Despite the potential protein, DNA methylation, and microRNA biomarkers for BE 
pathogenesis, only the acid mucins are used as diagnostic biomarkers for BE in the clinic. 
Upper endoscopy with biopsy remains the gold standard for diagnosis of BE and its 
progression to EAC. One significant impediment to furthering these techniques is the 
limited molecular understanding of BE development and its progression to EAC.  
Utilizing microRNA Signatures to understand BE Pathogenesis 
This study pursued biomarker signatures which could differentiate each stage of BE 
pathogenesis. The biomarkers of interest here are the microRNAs. These noncoding 
RNAs are between 11- 22 nucleotides in length and possess the ability to repress 
translation [131]. Each microRNA contains a seed sequence that is complementary to a 
region on its target genes’ transcripts. Usually, the mRNA target region is within the 3’ 
untranslated region (UTR) [132]. microRNAs bind as part of a RNA-induced silencing 
complex (RISC) [133]. microRNAs repress translation through two mechanisms, either 
by a physical block of ribosome binding or by recruitment of endonucleases [131] [134]. 
The RISC prevents ribosome binding to the target mRNA, leading to a reservoir 
population of microRNA-associated ribonucleoprotein complexes [135]. Some mRNA 
targets are then degraded, by removal of the poly A tail by GW182 and CCR4-NOT 
deadenylase complexes [133]. Repression of translation by microRNA does not require 
perfect complementarity between the seed sequence of the target. One microRNA can 
target hundreds of gene transcripts across multiple signaling pathways, making them 
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excellent indicators of disease [136-138]. MicroRNAs can also be introduced into the 
bloodstream as part of exosomes. MicroRNAs have been identified as biomarkers for 
colorectal cancer, breast cancer, diabetes mellitus, and traumatic brain injuries as well as 
many other diseases and conditions [139-143]. 
Many serum and tissue microRNAs have been found to be differentially expressed in BE 
and EAC [94]. None of these microRNAs are currently being used as a biomarker for BE, 
and no study to date has systematically identified any microRNA serum or tissue 
biomarkers for the development of BE. Despite the diverse roles microRNAs play in 
molecular signaling, microRNA biomarkers have not been utilized to identify pertinent 
signaling mechanisms in BE pathogenesis.  
This study seeks to examine the relationship between microRNA expression and the 
development and progression of BE. The first aim of this study was to identify a 
microRNA signature which could differentiate among all stages of BE pathogenesis. No 
such signature was identified. The second aim was to reveal microRNAs that were 
differentially expressed in pair-wise comparisons between stages of BE pathogenesis. 
Identified microRNAs appeared to be involved in EAC tumorigenesis or BE 
development. The third and last aim of this study was to determine the biological 
mechanisms and processes regulated by microRNAs differentially expressed in BE 
pathogenesis. Certain microRNAs identified in this study have roles in the regulation of 
posterior homeotic genes, which is consistent with the resemblance of BE to a homeotic 
transformation. 
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MATERIALS AND METHODS 
Small RNA-sequencing of microRNAs in Patient Tissue and Serum Biopsies 
Collection of Fresh-Frozen Tissue and Serum from Human Patients 
Tissue and serum sample collection was performed at Dayton Veteran Administration 
Hospital by Dr. Sangeeta Agrawal. Both tissue and serum samples were collected from 
each patient during routine upper endoscopy with biopsy appointments. For this study, 76 
tissue and serum samples were processed from 38 patients. Upon collection, fresh tissue 
biopsies were kept in 100mL RNA-later at -80°C. Upon collection, serum biopsies were 
kept in at -80°C until small RNA could be isolated. 
The patients included were classified into five groups: GERD, BE, BE with indefinite 
dysplasia, BE with low grade dysplasia and EAC. Patients were selected for this study 
based on their initial diagnosis prior to collection of tissue and serum samples. For this 
study, BE patients with indefinite dysplasia and BE patients with low grade dysplasia 
were combined into one group termed LGD.  
Tissue and serum samples from patients labelled Normal were also collected, yet this 
group is not included in the final analysis. The Normal group was intended as a negative 
control. However, after a preliminary analysis of the small RNA-seq data, it was 
observed that microRNA expression in the Normal group was more variable than the 
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other pathology groups in both serum and tissue. The Normal moniker only indicated the 
absence of GERD or BE in these patients. It did not account for the variety of other 
conditions which required the patient to undergo an upper GI endoscopy, thus they were 
not healthy controls. 
Prior to sequencing, small RNAs must be isolated from each sample and cDNA libraries 
prepared from the isolated small RNAs. Under advisement from Life Technologies, the 
manufacturer of the Ion Proton instrument, the patient tissue and serum samples were 
prepared for sequencing in slightly differing manners. However, sequencing of tissue and 
serum followed the same procedure. 
Small RNA Isolation from Patient Tissue Samples 
Small RNAs were isolated from homogenized tissues following the manufacturer’s 
protocol provided for the mirVanaTM ParisTM RNA and Native Protein Purification kit 
(#AM1556, ThermoFisher Scientific).  Fresh-frozen tissues were removed from RNA-
later and homogenized in 500mL Cell Disruption buffer. The tissue fragments were either 
chopped into small pieces with a razor blade and then homogenized with a small hand-
held homogenizer or homogenized with a rotor-stator homogenizer. All tissue 
homogenization was done on ice. Following small RNA isolation, the small RNAs were 
treated with the TURBO DNA-freeTM kit (#AM1907, ThermoFisher Scientific) to 
eliminate any possible DNA contamination. The lack of DNA contamination was 
confirmed by monitoring the isolated product by quantitative polymerase chain reaction 
(qPCR) for GAPDH amplification (#4333764T, Applied Biosystems).  
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Yield and quality of the isolated small RNAs were assessed through the Agilent 
Bioanalyzer small RNA kit (#5067-1548, Agilent Technologies). The Agilent 
Bioanalyzer (#G2939BA, Agilent Technologies) acts as a digital agarose gel. The virtual 
gel provides the percentage and concentration of microRNAs based on the size of 
oligonucleotides in the isolation product. Isolation products which contained over 30% 
microRNA were selected for sequencing and progressed to cDNA library preparation.  
Small RNA Isolation from Patient Serum Samples 
Although 1000μL serum is the recommended starting volume for small RNA isolation 
from serum, 1000μL serum was not available for every patient in this study. In order to 
limit introduction of variability into cDNA libraries made from the serum samples, the 
starting volume was reduced to 600μL serum for every patient. Small RNAs were 
isolated as directed by mirVanaTM ParisTM RNA and Native Protein Purification kit. 
Yield and quality by Agilent Bioanalyzer small RNA chip was not assessed for serum 
samples. Instead, the 20-30μL isolated product was concentrated to 5ul with a speed 
vacuum concentrator.  
cDNA Library Preparation of Tissue small RNAs 
Tissue cDNA libraries were prepared using the Ion Total RNA-seq v2 kit by Ion 
TorrentTM (#4479789, ThermoFisher Scientific). Per the kit protocol, the small RNA 
yield is diluted to 10 μg/μl with nuclease-free water, based on the microRNA 
concentration provided by the Agilent 2100 Bioanalyzer instrument. The small RNAs 
were hybridized with a proprietary mix of adaptors which were ligated to the 5’ end of 
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the small RNAs. The adaptors allow for the next steps which are reverse transcription to 
cDNAs and subsequent amplification of the cDNAs. The proprietary PCR primers 
require the presence of the hybridized adaptors in order to amplify the entire cDNA 
population. The 3’ primer also includes a barcode sequence. These barcode primers allow 
for patient samples to be differentiated from one another.  This enables pooling of 
multiple samples during sequencing and is essential later for data analysis.  With the 
inclusion of the adaptors and PCR primers, cDNAs reverse transcribed from microRNAs 
tend to be between 94-114 nucleotides. To filter cDNA libraries for this size range, a 
purification and size selection step was performed before and after cDNA amplification. 
Since tissue samples contain a vast number of varied nucleic acids, the rigorous protocol 
for the total RNA-seq v2 kit was utilized for purification and size selection, as it entails 
two ethanol washes.  
Following library preparation, the Agilent Bioanalyzer DNA 1000 chip (#5067-1504, 
Agilent Technologies) was used to determine the quality of each cDNA library. The 
DNA 1000 chip provides size ranges corresponding to small RNAs (50-300 base pairs) 
and to microRNAs (94-114 base pairs). These size ranges account for the addition of 
proprietary library primers and sequence adaptors to the cDNA libraries. Libraries with a 
high percentage of microRNAs (> 30%) and a high concentration of small RNAs (< 100 
nmol/l) underwent small RNA-sequencing.  
cDNA Library Preparation of Serum small RNAs 
Serum cDNA libraries were also prepared according to the Ion Total RNA-seq v2 kit 
protocol, except for the purification and size-selection steps. The initial concentration of 
23 
small RNA used for each serum cDNA library is unknown. However, the total volume 
from small RNA isolation was concentrated to 5μl, and 4μl of that volume initiated 
cDNA library preparation. 
Since the concentration of total RNAs in serum is assumed to be lower than fresh-frozen 
tissue, a less rigorous protocol for purification and size-selection is needed. Therefore, 
the Total Exosome RNA and Protein Isolation kit (#4478545, ThermoFisher Scientific) 
protocol was utilized for the purification and size-selection steps only.  
As with the tissue samples, quality and quantity of cDNAs derived from small RNA and 
microRNAs was assessed by the Agilent Bioanalyzer DNA 1000 chip.  
Small RNA-sequencing of microRNAs in Patient Tissue and Serum Biopsies 
In this study, the Ion ProtonTM system for Next-Generation Sequencing (Ion TorrentTM, 
Life Technologies) was utilized to sequence small RNAs in each patient tissue and serum 
sample.  
Small RNA-sequencing requires pooling of samples and another amplification of the 
cDNA libraries by emulsion PCR. First, each cDNA library was diluted to 5nM with 
nuclease-free water, and then up to 14 samples were pooled together and diluted to a final 
total cDNA library concentration. The Ion One TouchTM 2 system (#4474779, Life 
Technologies) was utilized for emulsion PCR. In emulsion PCR, every cDNA library 
fragment was ligated onto an Ion Sphere TM Particle (ISP) beads and then amplified (Ion 
PITM Hi-QTM OT2 200 kit, #A26434, Life Technologies). The 3’ primer for emulsion 
PCR contains a B primer sequence which can hybridize with the ISPs as well as the P1 
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adaptor sequences. A quality control step was included at this stage using the Ion 
SphereTM assay for the QubitTM 2.0 Fluorometer (#4468656, #Q32866, Invitrogen). The 
quality control metric was the percentage of ISP beads which contained successfully 
ligated cDNA library fragments, termed the Percent Templated ISPs. The minimum 
percentage suggested by the manufacturer is 10%. This percentage is derived from the 
fluorescence of two fluorescent probes, Alexa FluorTM 647 and Alexa FluorTM 488. Alexa 
FluorTM 647 binds to the A adaptor sequences. Alexa FluorTM 488 anneals to a site on the 
B primer sequence. For the Ion Proton system, less than 10% Templated ISPs could result 
in a lower amount of total sequenced reads for a small RNA-seq run (Appendix I). 
Ideally, each ISP was populated with only one cDNA library fragment. However, multi-
templated ISPs do occur. In this study, the Percent Templated ISPs was not an ideal 
indicator of their occurrence or the total reads sequenced in a small-RNA seq run 
(Appendix I). Following the QubitTM assay, the ISPs were loaded onto an Ion PI 
sequencing chip for small RNA-seq.  
Small RNA-sequencing required the Ion PITM Hi-QTM Sequencing 200 kit (#A26772, 
Life Technologies) and the Ion PITM Chip (#A26771, Life Technologies). The sequencing 
results underwent a preliminary analysis in the small RNA_analysis plugin provided by 
the Ion Torrent Suite v.5.10 software. The analysis plugin software provided the total 
small RNA reads and microRNA reads per patient sample. Raw sequences for those 
samples which yielded 200,000 or more microRNA reads were uploaded to Partek® 
Flow® (Partek Incorporated) to be converted to normalized microRNA read counts for 
analysis.  
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Preparing small RNA sequences for Analysis of Differential microRNA Expression 
Raw small RNA sequences are not ready fodder for analysis of differential microRNA 
expression, because the identity and quantity of microRNAs in each sample is not 
available. Here, Partek® Flow® software (Partek Incorporated) was utilized to convert 
the raw sequences (available in .fastQ format) into a more readily analyzed format: 
normalized microRNA read counts. Small RNA sequences from the 21 tissue samples 
were analyzed separately from the small RNA sequences for the 25 serum samples.  
Pre-Alignment Processing Removes Low Quality Bases from Raw Sequences 
Partek® Flow® allows for trimming of bases from the 5’end or 3’ end of sequenced reads, 
in order to maximize the alignment of reads to a reference database. In the sequencing 
process, both ends of a read are the result of more cycles than the middle portion, which 
predisposes base calls at either end to be less reliable.  
Standard practice is to trim sequences of bases with a Phred quality score below 20. A 
Phred quality score describes the likelihood of a miscalled base. A Phred quality score of 
20 is equivalent to a 1% probability of a miscalled base. To facilitate downstream 
processes, read lengths of approximately 170 base pairs were required. In order to obtain 
this read length for reads in all cDNA libraries, trimming was based on a Phred quality 
score of 19 or a 1.26% probability of a miscalled base. Sequences derived from 
microRNA products were between 94-114bp. Parameters for base trimming for the serum 
and tissue datasets maintained a minimum read length of 15bp.  
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Aligning the Raw Sequences to miRBase v.21 eliminates non-microRNA sequences from 
Analysis 
Following base trimming, the raw sequences were aligned to a genome reference. Since 
our interest was solely in microRNA expression, the genome reference was miRBase 
v.21, a database which has compiled the sequences of every known human microRNA
[144, 145]. In line with current literature and recommendations from Partek, the aligner 
algorithm used was the Bowtie aligner [146, 147]. Bowtie was constructed specifically to 
align short DNA sequences to larger genome references.  
Quantification of aligned reads to miRBase v.21 results in microRNA read counts 
In order to convert the raw sequences to microRNA read counts, the aligned sequences 
must be quantified. Here, the sequences were mapped to known human microRNA 
sequences using a microRNA annotation file from miRBase v.21. Partek® Flow®’s 
modified expectation/maximization (E/M) quantification algorithm provided estimated 
expression for each microRNA. Partek® Flow® documentation indicates this modified 
algorithm can also correct for any sequences which map to multiple locations in the 
human genome. Here, minimum seed length was set to 10bp with only 1 mismatch 
allowed between a read and a known microRNA seed sequence. 
Normalization of microRNA read counts by Trimmed Mean of M-values 
A Trimmed Mean of M-values (TMM) normalization was applied to the microRNA read 
count datasets for the tissue and serum samples [148-150]. This is to account for the 
variability in total microRNA reads in each patient sample, which can vary due to any of 
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the many technical steps required for small RNA sequencing. TMM was advantageous, 
because it does not use microRNAs with very low or very high expression for 
normalization. The distribution of microRNA read counts in the serum and tissue datasets 
was skewed to the right, due to the presence of those microRNAs with very high 
expression.  Instead, this method focuses only on the microRNAs for which the read 
count distribution in all samples approximates a Normal distribution.  
A portion of microRNAs had zero read counts in some tissue and serum samples, 
therefore an offset value of 1.00 was added to each read count value to prevent non-zero 
errors in the calculation of M-values in TMM normalization. This offset value also 
prevents non-zero errors in the calculation of expression fold change in downstream 
analyses. 
Filtering based on TMM-normalized microRNA read count applied to Serum and Tissue 
datasets 
Both the serum and tissue datasets were filtered in PartekTM FlowTM for microRNAs 
which contained 100 or more TMM-normalized microRNA read counts in 25% of patient 
samples. All downstream analyses were performed on the filtered serum and tissue 
datasets. This 100 microRNA read count filter was intended to reduce the absolute noise 
caused by microRNAs with very low read counts in most samples in the datasets. In 
addition, this threshold alleviates the possibility that significant differential expression is 
due to sequencing anomalies [151].  
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The minimum number of microRNA read counts permitted for each sequenced sample 
included in data analysis was 200,000. After alignment and quantitation to miRbase v.21, 
the minimum average read count for each microRNA in each sample was 77.28. Thus, 
setting the microRNA count threshold to 100 microRNA read counts was not a 
particularly stringent filter. This read count filter allowed for low read counts in one 
pathology group, while retaining enough in the three other pathology groups to allow for 
ready detection of any differential microRNA expression.  
Identification of Potential microRNA Signatures from Normalized microRNA Read 
Counts 
Since only a total of 21-25 patients were included in the serum and tissue analyses, this 
severely limits the statistical methods which can be utilized to analyze the filtered TMM-
normalized microRNA read count data. To identify microRNA signatures which could 
differentiate all the stages of BE pathogenesis, three general techniques were utilized: 
clustering analyses, Nearest Shrunken Centroids (NSC) classification, and the 
randomForest classifier.  
Here, the clustering analyses used were hierarchical clustering and a combination of a 
heat map analysis with k-means clustering. Both analyses were performed in the Orange 
Data Mining version 3.20.1 software [152].  
The R Statistical Programming software provides an interface for several statistical 
packages useful for analyzing large data sets [153]. The randomForest package in R is an 
excellent candidate to analyze the dataset in this study, as it allows for a large p and a 
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comparatively small n [154, 155]. Since BE pathogenesis follows a defined step-wise 
progression, classification randomForest and regression randomForest analyses were both 
deemed appropriate for this study. The regression component allows the regression 
randomForest to account for pathology order. For this analysis, the stages of BE 
pathogenesis were numbered sequentially with GERD being 1 and EAC being 4. Nearest 
Shrunken Centroids (NSC) analysis was performed using the pamr package in R [156].  
Pair-wise Comparisons Between Pathology Groups to Identify Candidate 
microRNAs 
Candidate microRNAs in this study are those microRNAs which are differentially 
expressed between two pathology groups. Identification and subsequent gene target 
analysis of these microRNAs was utilized to understand BE pathogenesis. 
The Partek® Flow® software contains a Gene Specific Analysis (GSA) function which 
allows grouping of samples into categories and pair-wise comparisons between the 
sample groups. Here, the patient samples were grouped by their pathology: GERD, BE, 
LGD, and EAC. To execute the comparisons, the Log Normal with Shrinkage (LNS) 
statistical model was selected as the best model for this study. The Akaike Information 
Criterion corrected (AICc) values for each microRNA tended to be lowest when utilizing 
the LNS model in our study and in a 2004 study by Burnham and Anderson [157]. The 
AICc values are measures of how well a statistical model fits a data set [158, 159].  
Partek ® Flow ® documentation regarding the use of LNS in the GSA suggests exclusion 
of features in the datasets with very low expression. To accomplish this, the lowest 
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average coverage value was increased from 1.0 to 4.0 in both the tissue and the serum 
analyses. This value was based on a visual examination of the LNS shrinkage plot 
generated in Partek ® Flow ®. This eliminated any microRNAs which had a geometric 
mean across all samples below 4.0. The comparisons made were according to the 
sequence followed by BE pathogenesis: BE vs GERD, LGD vs BE, EAC vs BE, and 
EAC vs LGD. The GSA algorithm then provided an uncorrected p-value and fold change 
for each microRNA in each sample. 
Before application of GSA algorithm, the total number of microRNAs aligned and 
quantified to miRBase v.21 was 2,588. After adjusting the lowest average coverage to 
4.0, the number of tissue microRNAs reduces to 1,193, while the number of serum 
microRNAs decreases to 718 microRNAs.  
In order to identify candidate microRNA biomarkers from each comparison, a Bonferroni 
threshold was applied to the p-values generated by the GSA [160, 161]. Here, 0.05 was 
set as the desired ɑ value, and the number of observations was equal to the total number 
of microRNAs.  
Gene Target Analysis for Selected Candidate microRNA biomarkers 
Two approaches exist to identify gene targets for a given microRNA from gene target 
databases. The first requires the use of a proprietary algorithm which predicts gene 
targets for a microRNA based on its seed sequence as well as other factors. Which factors 
are included in the algorithm differ based on the target database. This first approach is 
utilized by miRDB and TargetScan Human 7.2 (Table 2) [162-165]. The second approach 
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Table 2: Gene Target Analysis Utilizes Four Distinct Methods 
Method Target Type Filtering of Gene Target Results 
miRDB 
Predicted Target Prediction Score ≥ 80 
TargetScan 
Human 7.2 Predicted Cumulative weighted context ++ score < 0 
DIANA 
TarBase v.8 Experimentally-validated 





Validated by ≥ 1 luciferase reporter assay 
experiments 
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is experimental microRNA target identification. This can be achieved through a variety 
of high-throughput and low-throughput methods, including expression profiling 
following microRNA inhibition or luciferase reporter assays. TarBase v.8 from the 
DIANA toolbox provides a compilation of experimentally-validated gene targets for each 
microRNA, while miRNet includes gene targets from multiple target databases utilizing 
both approaches (Table 2) [166, 167].  
Several reference databases exist which have compiled experimentally-validated gene 
targets for many of the known human microRNAs. TarBase v8 and miRNet are two 
reference databases utilized to uncover gene targets for the six candidate microRNAs 
[166, 167]. Low-throughput assays are utilized for validation of microRNA gene targets, 
which are often first identified by genome-wide high-throughput screening experiments. 
Results from TarBase v8 were filtered for low-throughput assays only for this study 
(Table 2). Luciferase reporter assays are considered one of the most reliable low-
throughput assays to validate microRNA gene targets [168, 169]. The gene targets 
compiled by miRNet were filtered for those targets which were validated by luciferase 
reporter assay (Table 2). 
A gene’s expression can be indirectly affected by a microRNA. It is important to verify 
that a potential gene target contains at least one 6-8mer target site for a microRNA. 
Various algorithms have been created to predict microRNA targets based on microRNA 
sequence and potential target gene sequences. Here, Target Scan 7.2 and miRDB are two 
target prediction algorithms used to predict targets of the six candidate microRNAs 
(Table 2) [162, 165]. miRDB generates a prediction rank for each gene target. According 
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to the algorithm’s creators, a rank score above 80 is deemed acceptable [165]. Results 
from miRDB are filtered for targets ranking 80 or above (Table 2). 
Quantitative Real-Time PCR validation of Candidate microRNAs in Human Patient 
Tissues 
Another set of human patient tissues was obtained for validation of the small RNA-seq 
experiments. This cohort included 26 formalin-fixed paraffin-embedded (FFPE) samples 
from patients diagnosed with either Barrett’s Esophagus or Gastroesophageal Reflux 
Disease. The n for these experiments was based on the normalized microRNA read 
counts for the chosen candidate microRNAs obtained by small RNA-seq. 80% statistical 
power was desired, thus a total of 13 samples was necessary for each of the two 
pathology groups of interest.  
Total RNA was extracted from the FFPE tissues using the Covaris truXTRAC FFPE 
microtube RNA kit (Covaris, #520161). This method utilizes the Covaris Adaptive 
Focused Acoustics technology to remove the paraffin from the tissues prior to total RNA 
extraction. The protocol for the Covaris kit was followed with an additional wash with 
the provided ethanol-based buffer. Without the additional wash, guanidine ITC 
contamination was sometimes detected following elution off the Covaris-provided 
columns. Quality and quantity of total RNA yield was assessed via a ThermoFisher 
Nanodrop ONE spectrophotometer. The guanidine ITC contamination was indicated by a 
low 260/230 absorbance ratio.  
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cDNA synthesis and qPCR followed the protocol for the TaqMan Advanced microRNA 
assays (#A25576, #A28007). 10ng total RNA proved to be adequate starting material. 
The Applied Biosystems™ QuantStudio™ 7 Flex Real-Time PCR System was used to 
perform qPCR on four experimental plates. To assess differential expression of candidate 
microRNAs, the TaqMan® Advanced miRNA Assays for each candidate microRNA 
were selected (478230_mir, 478585_mir, 478769_mir). The ΔΔ Ct method was used to 
analyze the output of the qPCR experiments [170]. Since this is a relative quantitative 
method, an endogenous control microRNA was needed to provide the ΔCt values. 
Several endogenous control microRNAs are suggested by TaqMan®; however, there are 
no microRNAs which are known to keep constant expression in distal esophageal tissues. 
One of the suggested microRNAs, hsa-miR-423-5p (478090_mir) was chosen as the 
endogenous control microRNA as it did not display significant differential expression 
between the GERD and BE tissues in the small RNA-seq experiments.  
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RESULTS 
Small RNA-sequencing of microRNAs from Patient Serum and Fresh-Frozen Tissue 
Construction of cDNA libraries for small RNA-sequencing 
Thirty-eight patients were included in this study: 12 GERD, 9 BE, 6 LGD, 5 EAC, 5 
Normal, and 1 Esophageal Squamous Cell Carcinoma (ESCC). The ESCC sample 
initially had been identified as EAC.  When it was accurately identified as ESCC it was 
excluded from all further analyses.  At least one serum and one fresh-frozen tissue biopsy 
was collected from each patient at a routine upper endoscopy appointment. For small 
RNA-sequencing of microRNAs, cDNA libraries were constructed from small RNAs 
extracted from patient serum and fresh-frozen tissue. Total RNA was first extracted from 
each patient sample through a phenol extraction followed by a solid-phase extraction on 
glass-fiber filters. Small RNAs were enriched using a larger concentration of ethanol, 
thereby increasing their binding affinity for a second filter before elution into 40ul 
nuclease-free water.  
In the samples extracted from fresh-frozen tissue, a DNase-treatment was applied to 30ul 
extracted small RNA to eliminate any potential DNA contamination. Effectiveness of 
DNase treatment was verified by lack of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) amplification via qPCR. Then total small RNA concentration and microRNA 
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concentration were assessed by an Agilent 2100 Bioanalyzer (Figure 1). Generally small 
RNA samples with over 30% microRNA were selected for cDNA library preparation 
(Table 3). 10ng microRNA was utilized to construct cDNA libraries for the tissue 
samples.  
Small RNA samples extracted from patient serum were not treated with DNase or 
assessed by Agilent 2100 Bioanalyzer. It was determined that DNase treatment could 
detrimentally affect the already low yield of small RNA extraction from serum (Michael 
Zianni, Thermo Fisher Scientific, Personal Communication). Preliminary experiments 
with small RNA extraction from serum samples found that concentrations of small RNAs 
extracted from the serum samples were often below the quantitative range of the Agilent 
2100 Bioanalyzer (50-2000 pg/ul). This is not unprecedented, and in previous studies, a 
fixed volume was utilized rather than a fixed microRNA concentration for cDNA library 
construction [171]. The 30ul eluant from small RNA extraction was concentrated to 4ul 
using a Savant DNA Speed Vac Concentrator. 
For cDNA libraries constructed from either serum or tissue libraries, double stranded 
DNA/RNA adaptors from the Ion Adaptor Mix v2 (Ion Total RNAseq kit v2) were 
ligated to both ends of the small RNAs prior to reverse transcription (Figure 2).  These 
adaptors contain degenerate bases which allow for first strand synthesis. Size-selection 
for desired RNA products was then implemented by another solid-phase extraction. Here, 
the cDNA library fragments were bound to nucleic acid binding magnetic beads. For the 
tissue samples, the protocol first bound larger RNA products, such as from mRNA and 
rRNA, to the magnetic beads. Then the small RNA products were bound to beads with an 
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Figure 1: Assessment of small RNA and microRNA Yields following small RNA 
Extraction 
A representative small RNA sample extracted from patient tissue biopsy (Agilent 
Bioanalyzer small RNA chip). Peaks shown represent total small RNA from a 1 
microliter aliquot. Peaks between 10-40 nucleotides were considered microRNAs. 
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First Extraction Second Extraction Third Extraction 
1T 1634.49 1063.08 --- --- --- --- 
2T 1373.13 857.97 699.75 112.68 --- --- 
3T 1355.25 983.835 --- --- --- --- 
4T 205.38 9.9 170.64 21.87 158.4 9.45 
5T 1043.73 192.24 --- --- --- --- 
6T 281.205 51.435 310.41 49.05 --- --- 
7T 311.985 171.225 145.26 33.93 --- --- 
9T 977.85 694.17 343.08 97.56 --- --- 
11T 4027.68 2616.84 --- --- --- --- 
12T 856.35 222.66 1443.375 860.445 --- --- 
13T 1351.53 758.97 834.93 648.18 548.37 323.73 
15T 1013.85 539.73 1274.7 930.36 --- --- 
16T 291.21 45.66 1874.85 1232.76 1558.92 1077.36 
17T 1869.57 944.28 1468.86 723.18 --- --- 
18T 1270.89 690.21 --- --- --- --- 
19T 2087.19 1222.56 1769.22 1352.82 --- --- 
20T 2736.18 1633.5 1108.8 506.7 --- --- 
21T 2747.07 1585.08 1406.76 1089.9 --- --- 
22T 1292.49 885.15 --- --- --- --- 
23T 1314.45 829.71 --- --- --- --- 
24T 1849.23 1087.29 578.31 406.5 --- --- 
25T 1368.54 558.18 --- --- --- --- 
26T 3317.49 1990.53 406.53 141.39 --- --- 
27T 1807.74 823.23 718.92 472.59 --- --- 
28T 726.75 495 587.88 282.84 --- --- 
29T 1729.26 1032.39 --- --- --- --- 
30T 362.07 61.92 --- --- --- --- 
31T 1728.54 1109.16 --- --- --- --- 
32T 1674.36 889.65 2028.33 1523.565 --- --- 
33T 981.18 512.19 --- --- --- --- 
34T 529.83 221.49 1951.83 965.16 --- --- 
35T 1541.97 1224.27 --- --- --- --- 
36T 5867.46 3882.06 1812.6 1243.35 --- --- 
37T 986.4 402.345 1346.31 658.98 --- --- 
38T 8096.085 5249.16 3351.24 1851.03 --- --- 
39T 1016.505 390.645 --- --- --- --- 
40T 4171.14 1201.77 255.825 70.335 --- --- 
1 Agilent Bioanalyzer small RNA chip 
2 Samples indicated in boldface were used for cDNA library preparation. 
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Figure 2: Construction of cDNA libraries from Serum and Tissue small RNAs 
Small RNAs are hybridized with a mix of 5’ and 3’double-stranded DNA/RNA adaptors 
which contain 5’ and 3’ single-stranded extensions composed of degenerate bases. These 
extensions allow adaptor binding to all small RNAs within a sample. Following single-
strand synthesis and a size-selection protocol, a series of adaptors are added to the 5’ and 
3’ ends of the small RNA products. The A Adaptor and Key Sequence together are 30bp. 
The unique barcode sequence is 10bp. The 10 bp Internal Adaptor contains the 5’ primer 
binding site. The P1 Adaptor is 30bp in length. (Michael Zianni, Thermo Fisher 
Scientific, Personal Communication). 
42 
increased ethanol concentration. However, for the serum samples, this first step was 
deemed unnecessary due to the assumed low input RNA concentrations.  Therefore, the 
small RNA library size selection protocol from the Total Exosome RNA and Protein 
Isolation kit (#4478545, Life Technologies) was utilized for the serum derived cDNA 
libraries. This protocol simply requires binding of the small RNA products to nucleic acid 
binding magnetic beads, a wash step to remove larger RNA products, and then elution 
into 10ul nuclease free water.  
Following size-selection for small RNA products, three new adaptors were added during 
PCR amplification of the cDNA library (Figure 2). The 5’ A adaptor was 40 base pairs in 
length and included one of 16 unique barcodes. This 10bp barcode sequence was 
essential to differentiate among cDNA libraries following small RNA-seq. A 5’ 10 bp 
internal adaptor provides the binding site for the 5’ PCR primer. The P1 adaptor is 30bp 
in length and added to the 3’ ends of the library fragments. The A and P1 adaptors are 
necessary for small RNA-seq. After amplification of the cDNA libraries by PCR, another 
size-selection step identical to the first occurs.  The yield and size distribution for each 
purified cDNA library is then assessed in a quality control step via an Agilent 
Bioanalyzer DNA1000 chip. 
Selection of cDNA libraries for small RNA-sequencing 
Concentration of microRNA products in each cDNA library was determined by an 
Agilent 2100 Bioanalyzer (Figure 3). Since the adaptors and barcode total to 80 base 
pairs (Figure 2), cDNA library fragments derived from microRNAs (14-24bp) are 





Figure 3: cDNA library Selection is Based on the size of the 94-114bp peak 
Representative cDNA libraries constructed from patient tissue biopsy (Agilent 
Technologies DNA1000 chip). The first peak at 15bp and the last peak at 1500bp are an 
internal DNA standards provided in the Agilent Bioanalyzer DNA1000 chip kit. (A) A 
representative ideal cDNA library. Large peak at 94-114bp indicates a large 
concentration of microRNA products. The small peak adjacent to the 94-114bp peak was 
the adaptor-dimer peak. Any peaks above 300bp were other small RNAs. (B) A 
representative suboptimal library. The second largest peak at 89bp is considered the 
adaptor-dimer peak.  
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possessed a single large peak in this size range were selected for small RNA-seq. Peaks 
occurring before 94 base pairs were believed to belong to adaptor dimers. High 
concentrations of adaptor dimers, as depicted in Figure 3B, were thought to skew the 
sequencing results. Peaks after 114 base pairs generally were considered contamination 
by small RNAs, including tRNAs, indicating reduced effectiveness in size-selection 
during cDNA library construction.  
To maintain an appropriate number of patients per pathology group for sufficient 
statistical power, suboptimal cDNA libraries were included in the small RNA-seq 
experiments (Appendix II). 93 cDNA libraries derived from 69 serum or tissue samples 
were sequenced. Of those, several cDNA libraries were considered suboptimal as they 
contained large adaptor-dimer peaks. It became evident that small RNA-seq of cDNA 
libraries with large adaptor dimer peaks and small peaks at 94-114bp did not necessarily 
result in reduced sequencing of microRNA products (Appendix II). Some cDNA libraries 
with only the one large peak between 94-114 base pairs still sequenced large amounts of 
adaptor dimers and were not guaranteed to have high microRNA read counts in each 
sample. In this study, the peak trace provided by the Agilent 2100 Bioanalyzer was not a 
useful predictor of how well a cDNA library would sequence, in terms of microRNA read 
counts.  
Small RNA-seq of cDNA libraries prepared from Patient Serum and Fresh-Frozen Tissue 
Small RNA-sequencing was performed on the Ion Proton Next Generation Sequencing 
instrument using the Ion PI Hi-Q emulsion PCR and sequencing kits. Up to 14 cDNA 
libraries were pooled for each small RNA-seq run. The selected cDNA libraries were first 
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diluted to 5nM. The pooled cDNA libraries were then diluted to a final concentration 
ranging from 5pM-20pM.  
Even though the same concentration of cDNA library was included for each sample in 
each small RNA-seq run, it was observed that some samples sequenced substantially 
more microRNA read counts than others on the same Ion PI sequencing chip. In instances 
where this occurred, the samples that did not sequence well were sequenced on another 
chip and the pooled library concentration was increased to allow for more overall total 
reads per chip.  Initially, the 5pM pooled library concentration was intended to limit the 
number of reads sequenced by adapter dimers. However, the percentage of adapter dimer 
sequenced did not increase dramatically when the pooled library concentrations were 
increased to 15pM or 20pM (Appendix I).  
After sequencing 93 cDNA libraries over 16 small RNA-seq runs, a quality control step, 
the Ion Torrent smallRNA_analysis plugin, obtained a measure of microRNA reads 
sequenced for these cDNA libraries (Appendix II). This preliminary analysis aligned and 
quantitated the sequences for each sample to miRbase v20 [173, 174]. The number of 
microRNA reads for a cDNA library ranged from 16,829 – 13,538,600 reads (Appendix 
II). 21 cDNA libraries sequenced more than 1,000,000 microRNA reads, the threshold 
generally suggested by the manufacturer of the sequencing instrument. These libraries did 
not include enough of each pathology group to maintain sufficient statistical power in 
downstream analyses. To address this, the minimum microRNA read count threshold to 
select cDNA libraries for analysis was reduced to 200,000 microRNA reads. The 55 
cDNA libraries that passed this threshold included 12 BE, 10 EAC, 14 GERD, 10 LGD, 
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and 9 Normal serum or tissue samples (Appendix II). Due to the high variability in 
microRNA expression within the Normal patient group (Appendix III), the nine Normal 
samples were excluded from the analysis of the small RNA-seq data. The remaining 46 
cDNA libraries comprised of 25 serum samples and 21 tissue samples. Each stage of BE 
pathogenesis was represented by at least 5 patients (Table 4).  
The small RNA sequences from the 46 samples selected from this quality control step 
were converted to microRNA read counts in Partek Flow®. The small RNA sequences 
could originate from a variety of small RNA products, not just microRNA products. 
Therefore, sequences were aligned and quantitated to miRBase v.21 [144, 145]. This 
provided the raw read counts for all 2,588 known human microRNAs in each patient 
sample (Table 5).  
Normalization of microRNA read counts by Trimmed Mean of M-values (TMM) 
Total microRNA reads in each patient sample is variable, and this can affect downstream 
statistical analysis. To ensure all samples are comparable, a normalization method is 
applied to the microRNA read counts obtained after alignment and quantification to 
miRBase v.21.The Trimmed Mean of M-values (TMM) normalization method has a 
precedent for use with RNA sequencing [148-150]. The majority of microRNAs in the 25 
patient serum samples and the 21 patient tissue samples had 0-10 read counts (Figure 4). 
The similarities among the microRNA read count distributions for each sample indicated 
that most genes are not differentially expressed among the four pathology groups. This is 
an important observation, as TMM is only an appropriate normalization method for those 
data where a small fraction of genes are differentially expressed in an experimental group 
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Table 4: Composition of Serum and Tissue Sequencing Data Sets 
Pathology Serum Samples (n)1 Tissue Samples (n)1
GERD 8 6 
BE 7 5 
LGD 5 5 
EAC 5 5 
25 21 
1 20 Serum and Tissue came from the same patients. 
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Table 5: Selected Serum and Tissue Samples Processed and Aligned in Partek Flow 
Sample Pathology 
Total microRNA 
reads1 Sample Pathology 
Total microRNA 
reads1
13S EAC 204,003 13T EAC 449,663 
15S BE 413,519 15T BE 345,976 
16S LGD 183,935 16T LGD 335,729 
17S LGD 282,797 17T LGD 1,026,395 
18S BE 556,967 1T BE 300,635 
19S GERD 223,628 20T BE 1,400,802 
1S BE 883,503 21T GERD 309,603 
20S BE 1,227,629 23T GERD 176,626 
21S GERD 2,420,358 26T EAC 2,023,514 
23S GERD 1,277,820 27T EAC 397,774 
24S BE 537,818 28T LGD 1,246,450 
26S EAC 161,492 29T BE 165,614 
27S EAC 135,689 2T GERD 429,997 
28S LGD 152,250 32T GERD 825,618 
29S BE 553,629 33T BE 317,549 
2S GERD 302,725 34T EAC 411,163 
32S GERD 525,009 36T GERD 254,886 
33S BE 735,174 37T LGD 2,881,190 
34S EAC 177,121 38T EAC 1,977,969 
36S GERD 1,236,167 39T LGD 512,297 
37S LGD 4,239,575 6T GERD 1,089,611 
38S EAC 371,094 
39S LGD 1,109,802 
3S GERD 664,552 
7S GERD 2,969,782 
1Raw microRNA reads generated in Partek Flow 
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Figure 4: Distribution of Raw MicroRNA Read Counts in Serum and Tissue 
Samples 
Processing of small RNA sequencing and conversion to microRNA read counts was 
performed in Partek FlowTM. Each barplot was generated in Partek FlowTM. Each cDNA 
library sample was coded with a unique color. The y-axis is the number of known human 
microRNAs which occur in a sample for each read count category (x-axis). (A) Serum 
dataset (25 samples) following base trimming, alignment to miRbase v21, and 
quantification to miRbase v21. (B) Tissue dataset (21 samples) following base trimming, 
alignment to miRbase v21, and quantification to miRbase v21 
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[149]. TMM equates overall expression of all genes within the libraries, thereby 
decreasing the rates of false positives when analyzing the data for differential microRNA 
expression [149].  First, for a given microRNA, a ratio (x) between the raw microRNA 
read counts in each sample to the total number of read counts in that same sample were 
calculated: 
𝐹𝑜𝑟 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑚𝑖𝑐𝑟𝑜𝑅𝑁𝐴 𝑖𝑛 𝑎 𝑠𝑎𝑚𝑝𝑙𝑒:  𝑥 =  
𝑚𝑖𝑐𝑟𝑜𝑅𝑁𝐴 𝑟𝑒𝑎𝑑 𝑐𝑜𝑢𝑛𝑡𝑠
𝑡𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑑𝑠 
 Log-fold changes for each microRNA (M-values) compared these ratios between a given 










 𝑙𝑜𝑔  𝑥  × 𝑥  
Then, the M-values were trimmed by 30% and the A-values by 5% on both ends. The 
TMM normalization factor applied to the data set is derived from the weighted mean of 
trimmed M-values [149]. Since some of the 2,588 microRNAs displayed no expression in 
some of the serum and tissue samples, it was necessary to add an offset value of 1.00 to 
prevent non-zero errors in the TMM normalization.  
All subsequent data analyses were performed on the TMM-normalized microRNA read 
counts for the patient serum and patient tissue samples.  
53 
Applying a Minimum Normalized microRNA Read Count Filter to Serum and Tissue 
Datasets 
To ensure the candidate microRNAs revealed by these analyses were selected based on 
sufficient statistical power, a filter based on normalized microRNA read counts was 
applied to the serum and tissue datasets. For a given microRNA, 25% of the patient 
samples needed to contain 100 or more normalized microRNA read counts. microRNAs 
with 100 or more normalized read counts would be more likely to be detected by qPCR 
during validation experiments [151]. This filter removed any microRNAs that had low 
expression in every pathology group. Allowing for 25% of the samples to exhibit low 
normalized read counts enabled capture of any candidate microRNAs which might be 
lowly expressed in only one pathology group. For the serum and tissue datasets, the 
normalized 100 microRNA read count filter removed all but 187 and 272 microRNAs, 
respectively. 
Identification of Candidate microRNA Biomarkers for BE Pathogenesis in Patient 
Serum and Tissues 
The filtered TMM-normalized microRNA read counts for the serum and tissue data sets 
were analyzed separately by three different methods: unsupervised hierarchical 
clustering, Nearest Shrunken Centroids classification, and the randomForest classifier. 
The objective of these analyses was to reveal any potential microRNA signatures in the 
serum or tissue datasets which could differentiate all four stages of BE pathogenesis. 
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Hierarchical Clustering 
In hierarchical clustering, samples are clustered based on the extent of their similarities to 
each other. Similarities are determined by the Euclidean distances between microRNA 
read counts for each sample [175]. Clustering was based on the average Euclidean 
distances for all data points between two clusters, a method called average linkage [176]. 
Hierarchical clustering for this study was performed in Orange Dating Mining Tool Box 
v. 3.20.1 and visualized as a dendrogram [152]. For the serum dataset, all 187 filter
microRNAs were included in four distinct clusters (Figure 5A). In terms of pathology, 
the four clusters of serum samples were very heterogenous and a relationship between BE 
pathogenesis and microRNA expression was not apparent. When hierarchical clustering 
is applied to the 25 tissue samples, two larger clusters can be observed (Figure 5B). 
However, these clusters are also heterogenous in terms of pathology, and do not include 
six of the tissue samples. These six tissue samples consist of 1 GERD, 3 LGD, and 2 
EAC. It appears that normalized microRNA read counts cannot be used to group tissue 
samples based on pathology, according to this hierarchical clustering analysis.  
Visualization of the serum and tissue data sets by heat mapping demonstrates the 
difficulty of identifying microRNA signatures from 187 microRNAs or 272 microRNAs, 
respectively (Figure 6). In the heat maps, k-means clustering separates the microRNAs 
into a pre-determined number of clusters, based on proximity to calculated centroids 
[177, 178]. The centroid of a cluster is a point where the Euclidean distances among the 
data points are minimized. If a microRNA signature existed in either the serum or tissue  
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Figure 5: Hierarchical Clustering of Serum and Tissue Samples 
Hierarchical Clustering was performed and visualized in Orange Data Mining version 
3.20.1. Metrics used: Euclidean Distances and Average Linkage. (A) 25 serum samples 
clustered based on normalized microRNA read count data for 187 filtered microRNAs. 




Figure 6: Heat Maps of Serum and Tissue Samples 
Heat Maps were constructed in Orange Data Mining version 3.20.1.  k-means clustering 
(10 clusters) was used to group microRNAs. (A) 25 serum samples (x-axis) vs normalized 
microRNA read count data for 187 filtered microRNAs (y-axis). (B) 21 tissue samples (x-
axis) vs normalized microRNA read count data for 272 filtered microRNAs (y-axis). 
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data sets, it was expected that a cluster of microRNAs would display distinct differential 
expression in the heat map among the four stages of BE pathogenesis. 
Nearest Shrunken Centroids 
A classifier termed Nearest Shrunken Centroids (NSC) was used as an alternative to 
hierarchical clustering. NSC has been utilized previously to identify several genes which 
differentiate multiple types of round blue cell tumors [156]. NSC is advantageous in 
analyzing data with numerous variables and a significantly smaller number of samples, 
which described the serum and tissue small RNA-seq datasets. 
NSC was implemented through the PAMR package available for R. For each microRNA 
in each sample, a centroid was calculated for each pathology group by dividing the 
average microRNA expression by its standard deviation.  NSC is a supervised classifier, 
in that the groups must be defined beforehand. Then for each pathology group, the 
centroids were “shrunk” towards zero by a certain threshold value [156]. This threshold 
value is associated with a misclassification error percentage. Each microRNA was given 
a score based on their distance from the centroid after shrinkage. NSC outputs a 
combination, or signature, of microRNAs which can differentiate the predefined 
pathology groups from each other. If a microRNA possessed a non-zero score for a 
pathology group, that microRNA contributed to the signature’s ability to differentiate that 
pathology group from the other three pathology groups. 
When NSC was applied to the serum dataset, 185 of the 187 microRNAs showed non-
zero scores for at least one pathology (Figure 7). This indicates that these 185  
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Figure 7: Serum microRNAs cannot distinguish among Four Stages of BE 
Pathogenesis  
Nearest Shrunken Centroids (PAMR package in R) analysis applied to 25 Serum 
samples, based on TMM-normalized read counts for the 187 filtered microRNAs. A 
representative sample of 185 microRNAs are shown here. These 185 microRNAs were 
associated with the least number of misclassification errors for each pathology group in 
the NSC analysis and an overall misclassification rate of 44.6%.  
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microRNAs could operate together as a microRNA signature to differentiate every 
pathology group in BE pathogenesis. However, the overall misclassification rate for these 
microRNAs was 44.6%. The misclassification rates for each pathology group ranged 
from 20% -80%. While many serum microRNAs may be differentially expressed in BE 
pathogenesis according to the NSC analysis, the misclassification rate is too high for 
these microRNAs to function as a signature for every stage of BE pathogenesis. 
In the tissue dataset, 23 of the 272 microRNAs have non-zero scores for one or more of 
the four pathology groups (Figure 8). The overall misclassification rate for this analysis 
was 47.5%. Most microRNAs in this potential tissue microRNA signature appear to be 
specific to LGD or EAC. However, the misclassification rates associated with these 
pathology groups was 40% and 80%, respectively. One microRNA had a non-zero score 
for the GERD pathology group, miR-126-5p. No microRNAs were able to differentiate 
the BE group from the other pathology groups, Therefore, this 23 microRNA signature 
could not function as a biomarker panel for BE pathogenesis.  
randomForest 
A decision tree can separate tissue or serum samples into the pathology groups based on 
the TMM-normalized microRNA read count data (Figure 9). A single decision is prone to 
over-fitting [179]. randomForest is a supervised machine learning method which samples 
with replacement from the dataset to build a “forest” of decision trees [154, 155]. Two 
different randomForest techniques were utilized in this study: randomForest classification 
and randomForest regression. The classification randomForest separates the samples into 
previously assigned groups using 1 million decision trees created from the microRNA  
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Figure 8: Tissue microRNAs cannot distinguish among Four Stages of BE 
Pathogenesis 
Nearest Shrunken Centroids (PAMR package in R) analysis applied to 21 Tissue 
samples, based on TMM-normalized read counts for the 272 filtered microRNAs. These 
23 microRNAs were associated with the least number of misclassification errors for each 
pathology group in the NSC analysis and an overall misclassification rate of 47.5%. 
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Figure 9: Decision Trees Can Separate Tissues into the Four Pathology Groups 
Representative decision tree was generated in Orange Data Mining version 3.20.1. 
from TMM-normalized read counts for six select microRNAs from the Tissue dataset 
(21 total samples).  
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read count data. The microRNAs are ranked by mean decrease accuracy, which indicates 
the importance of a microRNA in constructing the randomForest. A high mean decrease 
accuracy occurs if the accuracy of the model decreases when the microRNA is removed 
from the randomForest. A measure of predictive error for this analysis is the out of bag 
(OOB) estimate of error rate.   
randomForest regression includes an extra component of sample order. Since BE 
pathogenesis is a step-wise malignant progression, the pathology groups were numbered 
sequentially with GERD being 1 and EAC being 4.  Instead of Mean Decrease Accuracy, 
a microRNA’s importance in the randomForest regression is indicated by the percentage 
the mean squared error (%IncMSE) of the predictions increases as a result of removing 
the microRNA. There is not an equivalent metric of OOB estimate of error rate for the 
randomForest regression 
randomForest classification 
As can be observed in Figure 10A, miR-190a-5p is considered the most important 
microRNA in classifying the 25 serum samples into the four pathology groups. The 64% 
OOB estimate of error rate for the serum randomForest classification was not due to a 
misclassification of any particular group. All the pathology groups had at least 50% of 
their samples misclassified into the incorrect pathology group. Only LGD had a 100% 
misclassification rate; all 5 samples misclassified as either EAC, BE, or GERD. 
miR-196b-5p and miR-196a-5p are the top two most important microRNAs for 
classifying the four pathology groups, according to the tissue randomForest classification 
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analysis (Figure 10B). Here, the OOB estimate of error rate was 67%. All 5 EAC tissue 
samples misclassified as either BE or LGD, and four out of six GERD samples 
misclassified as either EAC, LGD, or BE. As in the serum analysis, no single pathology 
group contributed to the large OOB estimate of error rate. 
Since randomForest separates data into groups using decision trees, it will tend towards a 
focus on all variability in the data, rather than just the differences between pathology 
groups. This is especially true when less than 5 groups are assigned in a dataset. This may 
account for why even the most important microRNAs from the serum or tissue datasets 
were not good classifiers of BE pathogenesis. 
randomForest regression 
In the serum analysis, miR-190a-5p, miR-194-5p, and miR-106b-3p had the highest 
%IncMSE values. These microRNAs appeared to be the most important microRNAs in 
accurately predicting a sample’s pathology and its order in BE pathogenesis (Figure 
11A). In tissue, miR-196b-5p, miR-223-3p, and miR-196a-5p rank most highly, 
according to their %IncMSE values (Figure 11B).  
Conclusions 
It was clear from the hierarchical clustering and NSC analyses that a microRNA 
signature for BE pathogenesis was not detectable in the serum data sets. The NSC 
analysis of the tissue data set did provide a large potential signature of microRNAs which 
could differentiate all four stages of BE pathogenesis. However, this was associated with 
high misclassification rates for each pathology group. While several serum and tissue  
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Figure 10: randomForest classification on Serum and Tissue datasets 
randomForest classification was performed in the randomForest package available for R. 
(A) 187 Filtered Serum Samples. (B) 272 Filtered Tissue Samples
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Figure 11: randomForest regression on Serum and Tissue datasets 
randomForest regression was performed in the randomForest package available for R. (A) 
187 Filtered Serum Samples. (B) 272 Filtered Tissue Samples 
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microRNAs ranked as the most important classifiers for BE pathogenesis in the 
randomForest analyses, misclassification rates for each pathology were still not ideal.  
For this study, a microRNA signature for BE pathogenesis was not readily apparent in 
either the serum or tissue samples when analyzed by hierarchical clustering, NSC, or 
randomForest.  
Gene Specific Analysis Identifies Single Candidate microRNAs through Pair-Wise 
Comparisons 
Gene Specific Analysis (GSA) in Partek Flow allows for comparisons between two 
groups in a data set and generates a p-value for each of the 2,588 microRNAs aligned to 
miRBase v21, based on a selected statistical model. This GSA tested differential 
expression between BE vs GERD, LGD vs BE, EAC vs BE, and EAC vs LGD. The EAC 
vs BE comparison was included as BE patients can progress quickly through the LGD 
step to develop EAC.  
Since GSA entails multiple comparisons, a Bonferroni correction  is necessary to 
establish a limit to Type I statistical errors [180]. This correction entails dividing an α 
value by the number of pair-wise comparisons. The α describes the permissible false 
positive rate, while the number of pair-wise comparisons are those microRNAs which 
passed the minimum read count filter. 
Serum 
When a false positive rate of 5% was permitted ( = 0.05), none of the microRNAs 
passed the Bonferroni threshold applied to the GSA results. When  was increased to 0.1, 
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only miR-194-5p showed significant downregulation in serum of EAC patients in 
comparison to BE patients (Table 6). This indicates that differential microRNA 
expression among the four stages of BE pathogenesis cannot be detected in the 24 patient 
serum samples. miR-194-5p is in the top four and the top two most important 
microRNAs in the serum randomForest classification and regression analyses, 
respectively. miR-194-5p has previously been found to have increased expression in 
tissue and serum of BE patients [94]. 
Tissue 
Of the 272 microRNAs, only three passed the Bonferroni threshold with  set to 0.05 
(Table 6). Three additional microRNAs were included when  was reduced to 0.1 (Table 
6). miR-196a-5p, miR-196b-5p, and miR-215-3p were all upregulated in BE patient 
tissues when compared to the 6 GERD patient tissues. miR-596 showed downregulation 
in EAC patient tissues, in comparison to LGD. However, miR-596 did not pass the 
Bonferroni threshold in the BE vs EAC comparison. Expression of miR-223-3p was 15-
fold higher in the EAC vs BE patients. miR-4655-3p was downregulated in EAC vs BE. 
Yet, neither miR-223-3p nor miR-4655-3p were found to be significantly differentially 
expressed in either the BE vs LGD or EAC vs BE comparisons. In previous studies, miR-
196a-5p, miR-196b, miR-215, and miR-223 have all been shown to be upregulated in BE 
tissues [94]. 
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Table 6: Seven microRNAs display Differential Expression in Stages of BE pathogenesis 
α microRNA Adjusted p-value1 Fold Change 
Serum (BE vs EAC) 
0.1 miR-194-5p 0.05928 -6.74
Tissue (BE vs GERD) 
0.05 miR-196b-5p 0.00048 23.20 
0.05 miR-196a-5p 0.01994 18.30 
0.1 miR-215-3p 0.05930 37.90 
Tissue (LGD vs BE) 
0.1 None Passed Threshold 
Tissue (EAC vs BE) 
0.05 miR-223-3p 0.00588 15.00 
0.1 miR-4655-3p 0.05930 -15.10
Tissue (EAC vs LGD) 
0.1 miR-596 0.06174 -13.00
1 p-values Bonferroni-corrected for multiple comparisons.
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randomForest analysis of BE and GERD Tissue Samples support Findings from Gene 
Specific Analysis 
miR-196a-5p and miR-196b-5p were identified as important microRNAs for overall 
classification of the tissue samples into the four pathology groups, according to both 
randomForest analyses (Figures 10 and 11). miR-223-3p, miR-4655-3p and miR-596 also 
appear to be the top 20 most important microRNAs in the tissue randomForest analyses. 
To determine how well the microRNA candidates from the GSA classify the samples into 
their corresponding pathology groups, miR-196a-5p, miR-196b-5p, and miR-215-3p 
were analyzed again by randomForest classification. Instead of including all four 
pathology groups, only BE and GERD tissues were included in this follow-up analysis. 
miR-196a-5p and miR-196b-5p ranked first and fourth among the 272 microRNAs, 
indicating their ability to differentiate BE and GERD. When the input data is limited to 
only the three microRNAs of interest, 1 out of 5 BE samples and 0 of 6 GERD samples 
were misclassified. The overall error rate for these microRNAs was 9.09%. As only 5-6 
patient samples are included in each pathology group, the randomForest analyses were 
not particularly robust validation methods for the GSA results. Analysis of only these 
three microRNAs in the BE and GERD groups by hierarchical clustering or heat mapping 
did not reveal clustering based on pathology. The randomForest classifier does lend 
further support to the candidacy of these microRNAs as biomarkers. Since the small 
sample size of the small RNA-seq study prevents validation by in silico methods, a qPCR 
study on a larger sample set is necessary to validate the candidate microRNA biomarkers. 
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Validation of Small RNA-Sequencing Results by Quantitative real-time PCR 
Preparation of cDNA libraries for small RNA-seq and the sequencing technology itself 
can introduce technical biases to data [181]. Therefore, it is necessary to confirm small 
RNA-sequencing results by another technique [182]. qPCR is a technique renowned for 
its accuracy and specificity in RNA expression [183]. It is considered the obligatory 
technique for validation experiments for small RNA-sequencing studies. 
The three BE vs GERD microRNA candidates were chosen for qPCR validation in this 
study. miR-196b-5p, miR-196a-5p, and miR-215-3p have the lowest p-values of all the 
microRNAs which passed either of the Bonferroni correction thresholds. All three of 
these microRNAs are significantly upregulated in the BE patient tissues when compared 
to the GERD patient tissues (Table 6).  GERD is estimated to affect 20% patients in the 
United States [184]. Since BE lesions do not present additional symptoms, the actual 
number of GERD patients with BE is unknown. GERD patients with undiagnosed BE 
still have the same heightened risks of dysplasia and EAC but do not undergo 
surveillance. The three BE vs GERD candidates could become confirmatory biomarkers 
for BE in GERD patients.  
Since the small RNA-seq study included a small number of human patient samples, the 
variance in microRNA read counts, even in the same pathology group, could be large. 
For example, the variance among microRNA read counts in the BE patients was 
noticeably larger than the variance in the GERD patients, especially for miR-215-3p 
(Figure 12). The heightened variability in the BE tissues for miR-215-3p may account for 

























Figure 12: Three microRNAs show significant increased expression in BE Tissues vs 
GERD Tissues  
TMM-normalized microRNA reads counts obtained by small RNA-seq for the three BE 
vs GERD candidate microRNAs show increased expression and larger variance in the BE 
patient tissues.  
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Power Analyses of Tissue microRNA Candidates 
A separate cohort of formalin-fixed paraffin-embedded (FFPE) tissues from 13 GERD 
and 13 BE patients was utilized for the qPCR validation studies. The sample number (n) 
of these studies was selected based on power analyses performed for each of the three 
candidate microRNAs (Table 7). These analyses were done using the GERD vs. BE 
microRNA read counts obtained from the small RNA sequencing libraries (Table 7). 
Though miR-196a-5p and miR-196b-5p required eight and seven samples to achieve 80% 
power, 13 samples per pathology group were needed to achieve sufficient statistical 
power for miR-215-3p.  
Total RNA Extraction from Formalin-Fixed Paraffin-Embedded Tissues required 
Optimization 
Total RNA was extracted from the FFPE tissues by the Covaris truXTRAC FFPE RNA 
microtube kit which utilizes the Covaris M220 Acoustic Focused ultra-sonicator. Initial 
total RNA extractions contained guanidine ITC contamination, noted upon assessment by 
NanoDrop ONE. Guanidine salts are a component of the Covaris kit necessary for the 
column chemistry. Total RNA was re-precipitated from these samples using a sodium 
hydroxide/ethanol precipitation protocol. Subsequent total extractions included a third 
wash with the Covaris ethanol wash buffer, which appeared to resolve the guanidine salt 
contamination. Total RNA concentration was obtained by NanoDrop ONE (Table 8). 
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Table 7: Power analysis for qPCR validation 
TMM-Normalized microRNA Read Counts Samples Required2 
microRNAs1 GERD (mean) BE (mean) 
Standard 
Deviation GERD (n) BE (n) 
miR-196a-5p 26.43 484.09 305.22 8 8 
miR-196b-5p 18.89 438.03 264.20 7 7 
miR-215-3p 12.77 483.61 410.24 13 13 
1 MicroRNAs identified as differentially regulated in the GERD vs. BE comparison in 
tissue samples based on small RNA-seq data. 
2 Minimum number of samples required to obtain power of 0.8 with an σ of 0.05.  
Power analyses based on TMM-normalized microRNA read counts from tissue small 
RNA-seq 
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Table 8: Total RNA Extracted from Formalin Fixed Paraffin Embedded Tissues1







3524B BE  1,152 1.83 1.03 
2925B BE  826 1.83 1.41 
2427F BE  1,082 1.86 1.59 
2401B BE  1,344 1.88 1.73 
505E BE  2,763 1.93 1.94 
4176B BE  1,050 1.90 1.26 
3983D BE  1,180 1.87 1.68 
3694C BE  385 1.71 1.98 
766E BE  749 1.82 1.29 
5138C BE  1,306 1.86 1.53 
1507F BE  1,054 1.90 1.79 
2244C BE  1,985 1.93 1.78 
1689G BE  1,750 1.90 0.57 
1823H BE  529 1.72 2.16 
1976B BE  1,432 1.90 1.64 
2374C GERD  2,114 1.82 2.16 
4268E GERD  977 1.69 2.25 
2493- GERD  830 1.76 2.05 
1849B GERD  1,050 1.65 2.09 
2870A GERD  221 1.64 1.67 
2024A GERD  1,428 1.65 1.95 
5791B GERD  1,876 1.67 1.22 
5281D GERD  567 1.60 1.23 
1927B GERD  1,687 1.81 1.54 
1923E GERD  1,316 1.70 1.35 
1833A GERD  2,027 1.85 1.74 
6302D GERD  872 1.74 1.36 
5751A GERD  557 1.64 1.06 
5307C GERD  532 1.67 0.90 
1  Extracted by Covaris TruXTRAC FFPE RNA microTUBE kit (Covaris M220 Focused 
Ultrasonicator) 
2  Measured by NanoDrop ONE spectrophotometer 
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Quantitative real-time PCR for 13 GERD and 13 BE Tissue Samples 
cDNA for the qPCR experiments was synthesized from 10ng total RNA by the TaqMan 
Advanced microRNA cDNA synthesis kit. Since no quality control step is included to 
assess cDNA quantity and quality prior to qPCR, the 10ng starting amount is necessary to 
ensure a common baseline among the 26 samples. 
In this study, each microRNA was assessed in triplicate for each BE and GERD sample. 
Ct values for the biological replicates were the average of the technical replicates. Since 
the analysis utilized, the ΔΔCt method, is a relative quantitative method, an endogenous 
control microRNA was chosen to normalize the data from the three experimental 
microRNAs. miR-423-5p did not show significant differential expression between the 
GERD and BE patient tissues in the small RNA-seq experiments (Figure 13). In the 
qPCR experiments, miR-423-5p expression significantly differed in the BE FFPE tissues 
when compared to the GERD FFPE tissues. However, this difference was in the same 
direction as the expression difference for the three experimental microRNAs (Figure 14). 
While this indicated that miR-423-5p was not a perfect control microRNA for qPCR in 
distal esophageal tissues, its effect on the overall results of the ΔΔCt calculations 
appeared to have been minimal.  
After the average Ct values for each experimental microRNA are normalized to miR-423-
5p, a Student’s T-test was performed on the ΔCt values. It should be noted that the lower 
the Ct value, the more abundant and more highly expressed the microRNA in the tissue 
sample. As shown in Figure 15, miR-196b-5p showed the most significant difference 














Figure 13: miR-423-5p is not significantly differentially expressed between GERD 
and BE tissues  
TMM-normalized microRNA reads counts for miR-423-5p were obtained by small RNA-
seq. A Student’s t-test performed between GERD patient tissues and the BE patient 
tissues for miR-423-5p produced a p-value of 0.8919. Box plot and Student’s T-test were 































Figure 14: miR-423-5p does not display constant expression between GERD and BE 
FFPE tissues 
Average Ct values for miR-423-5p were obtained by qPCR. Student’s t-tests performed 
between GERD patient tissues and the BE patient tissues for miR-423-5p and three 
experimental microRNAs produced the following p-values: *: p-value = 4.87 x 10-2  **: 
p-value =6.84 x 10-3 ***: p-value= 6.01x10-6 ****: p-value= 3.42x10-6
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Figure 15: miR-196a-5p, miR-196b-5p, and miR-215-3p all display significantly 
increased expression in BE tissues in comparison to GERD Tissues  
Average Ct values for each microRNA were obtained by qPCR. ΔCt values for each 
microRNA were normalized to miR-423-5p. A Student’s t-test was used to calculate p-
values for pair-wise comparisons between GERD patient tissues and the BE patient 
tissues.  
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and randomForest results, miR-196b-5p was also the most significantly changed between 
GERD and BE, thus this microRNA is a compelling candidate tissue biomarker for BE in 
GERD patients.  
Expression fold change (2-ΔΔCt) was calculated for each microRNA. As expected, all were 
upregulated in BE vs. GERD (Table 9).  The significant changes in the expression levels 
of these microRNAs indicate that miR-196b-5p, miR-215-3p, and miR--5p are 
potential tissue biomarkers for BE in GERD patients. 
Gene Target Analysis Reveals Potential Regulation of Homeotic Genes by 
Candidate microRNAs 
MicroRNAs can be utilized as clinical biomarkers to diagnose disease; however, they 
also can be utilized to increase understanding of a disease’s molecular mechanisms. For 
each candidate microRNA, lists of predicted gene targets from TargetScan Human 7.2 
and miRDB were compared to experimentally-validated targets found through TarBase 
v8 and miRNet [145, 162, 165-167, 185]. Preference was showed for those predicted 
gene targets which were also experimentally-validated. Additional insight into the impact 
of the candidate microRNAs on the molecular mechanisms behind BE development was 
gained through PubMed.gov literature search. 
BE vs GERD candidate microRNAs: miR-196a-5p, miR-196b-5p, and miR-215-3p 
miR-196a-5p and miR-196b-5p show similar but not exact microRNA read counts in the 
5 BE and 6 GERD patient tissue samples. The sequences for these two mature 
microRNAs differ by only a single nucleotide [186]. However, the two genes, MIR-196a- 
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Table 9: Change in Expression of selected microRNAs in BE vs. GERD FFPE tissues. 




1 ΔΔCt = ΔCtBE – ΔCtGERD 
2 Expression Fold Change = 2-ΔΔCt
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1 and MIR-196a-2, which can generate miR-196a-5p are located on Chromosome 12 and 
17. miR-196b-5p is a product of the MIR-196b gene on Chromosome 7.
The gene target analysis for both microRNAs showed midcluster and posterior HOX 
genes from the A, B, and C clusters as common targets (Table 10). miR-196a-1 and miR-
196b-1 are located intergenic to the HOXB and HOXC clusters, respectively [186]. The 
genes are both located in between the HOX9 and HOX10 genes. Due to the collinearity 
of HOX genes, their position could indicate that the microRNAs are transcribed when 
posterior HOXB and HOXC genes are activated. miR-196b is located intergenic to the 
posterior genes of the HOXA cluster.  
Gene targets for miR-215-3p have not been well-studied. Both target prediction 
algorithms did not return results for miR-215-3p. Investigations into TarBase v8 and 
miRNet only produced one target, FOXO1, which was validated to be a target of miR-
215-3p by luciferase reporter assay [187]. FOXO1 is also an experimentally-validated
target of miR-196a-5p [188]. An additional literature search revealed another target 
validated by luciferase reporter assay: BMI1 [189]. BMI is considered a catalytic subunit 
of the Polycomb Repressive Complex 1 (PRC1), a well-known silencer of HOX and 
other developmental genes [190].  
EAC vs BE candidate microRNAs: miR-223-3p and miR-4655-3p 
miR-223-3p is a microRNA known to be dysregulated in numerous cancers, including 
hepatocellular carcinoma, leukemia, lymphoma, and EAC [191-196]. The role of miR-
223-3p in cancer seems to vary depending on tissue type. In hepatocellular carcinoma,
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Table 10: Selected Gene Targets for the Three Candidate Tissue microRNA Biomarkers 
     miR-196a-5p targets     miR-196b-5p targets      miR-215-3p targets 
Gene 3’ UTR seeds Gene 3’ UTR seeds Gene           3’ UTR seeds 
HOXB71,2,4 1 HOXB71,2,4 1 FOXO12,4 1 
HOXC81,2,3,4 4 RDX1,4 1 BMI15 δ 
HOXA71,2,4 5 HOXC81,2,4 4 
HOXB82,4 1 HOXA91,2,3,4 2 
FOXO13,4 δ FAS3,4 1 
HOXA53,4 1 HOXA71,2 5 
HOXA91 2 HOXA51,2 1 
HOXB61 1 HOXB61,2 1 
HOXB12 1 HOXB82 1 
HOXB12 1 
1miRDB 
2TargetScan Human 7.2 
3DIANA TarBase v8 
4miRNet 
5 Jones et al., 2015 [186] 
δ Partial seeds or no seeds were indicated 
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miR-223-3p is downregulated and is thought to take on a tumor suppressive role [191]. 
Streppel et al (2013) found that this microRNA displays a step-wise increase in BE 
pathogenesis [196]. In that same study, overexpression of miR-223-3p in EAC cell lines 
promotes migration and invasion. In the small RNA-seq data, miR-223-3p showed 
significantly increased expression in the 5 EAC patients, in comparison to the 5 BE 
patients (Table 6). However, significant differential expression was not observed between 
LGD and BE or EAC and LGD.  
miR-223-3p has hundreds of predicted and experimentally-validated gene targets. Input 
of its gene targets found via the four methods into DAVID 6.8 Functional Annotation 
tool indicated these genes play roles in FOXO, AMPK, and PI3K-Akt signaling [197]. 
miR-223-3p does not appear to directly target HOX genes from any of the four clusters. 
miR-4655-3p is not a well-studied microRNA. None of its predicted targets from miRDB 
or TargetScan Human 7.2 have been experimentally validated. Two studies have shown 
that miR-4655-3p is differentially expressed in colorectal and triple negative breast 
cancer cell lines [198, 199]. This may be due to the location of miR-4655, the gene 
encoding miR-4655-3p, on chromosome 7. This gene is intragenic to the mitotic arrest 
deficient 1 like 1 [200], the human homolog for the Drosophila MAD1 gene [200, 201]. 
MAD1L1 is a mitotic check point whose function is affected by chromatin instability in 
cancer [200]. In colon cancer cell lines, this gene has been found to promote resistance to 
doxorubicin [202]. The downregulation of miR-4655-3p in EAC may be due to decreased 
transcription of the MAD1L1 gene in those tissues. 
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EAC vs LGD candidate microRNAs: miR-596 
The gene encoding miR-596 is in a portion of Chromosome 8 which is associated with 
breakage in cancer [203, 204]. According to the initial gene target analysis, the only miR-
596 gene target validated by luciferase reporter assay has been LGALS3BP, a secreted 
galectin-3 ligand [205]. Increased expression of this ligand is associated with poor 
prognosis in cancers [205]. LGALS3BP is thought to activate components of ERK1/2 
signaling, thereby promoting cell proliferation and inhibiting apoptosis [205]. A further 
literature review concerning miR-596 procured another experimentally-validated target: 
Smurf1 [206]. Smurf1 is a known negative regulator of p53, as it binds to and stabilizes 
MDM2, a prominent p53 inhibitor [206]. The downregulation of miR-596 in EAC patient 
tissues would lead to released MDM2 inhibition of p53 and increased expression of 
LGALS3BP and its action on ERK1/2 signaling.  
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DISCUSSION 
Limitations in Identifying Biomarkers for BE pathogenesis 
Identification of microRNA biomarkers in serum and tissue for clinical use faces 
numerous challenges as there is no standardized methods for RNA extraction, cDNA 
synthesis, or statistical analyses of differential microRNA expression [171, 207]. In this 
study, no combination of microRNA biomarkers was found in the analysis of the small 
RNA-seq data from either patient tissue or serum. This may be for multiple reasons. 
Serum 
Only one serum microRNA, miR-194-5p, could differentiate between two of the four 
pathology groups in this study. miR-194-5p was significantly decreased in the serum of 
EAC patients when compared to BE patients (Table 6). miR-194-5p was an important 
microRNA in the classification and regression randomForest analyses (Figures 10 and 
11) for the serum data set, indicating it may differentiate all four pathology groups from
each other. However, in the GSA for the serum data set, its expression was not 
significantly different between the LGD and EAC groups or the BE and LGD groups. 
miR-194-5p has been identified as an upregulated microRNA in tissue and serum of BE 
patients in numerous previous studies [94].  
Circulating microRNAs from serum or plasma have been used as diagnostic biomarkers 
for many diseases and conditions, such as adult-onset Still’s disease, ectopic pregnancy, 
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and hepatocellular carcinoma [208-210]. Success in identifying these microRNAs as 
biomarkers may be based on the characteristics of the conditions studied. Some of these 
conditions, such as adult-onset Still’s disease and ectopic pregnancy, are systemic. 
Changes which occur throughout the body, rather than in a localized region, would be 
more likely to generate a unique microRNA signature which could be associated with 
that condition. Cancers like hepatocellular carcinoma can be localized to a single tissue 
type. However, tumor-derived exosomes have been shown to provide a unique signature 
in the bloodstream [211].  
Chronic atrophic gastritis (CAG) bears many similarities to BE, as both diseases are 
precancerous lesions characterized as an intestinal metaplasia in an anterior organ [112, 
212]. Ten differentially expressed serum microRNAs have been detected in CAG, when 
compared to chronic non-atrophic gastritis. Of these ten microRNAs, miR-148a-3p, miR-
320a, miR-451a, miR-486-3p, miR-486-5p, and miR-92a-3p showed similar though not 
statistically significant differential expression in BE tissue and serum in comparison to 
GERD patients. The difficulty in studying serum microRNAs in both diseases is that the 
aberrant cell types are also present in the small intestine. Any microRNA signature 
exported from the metaplastic lesions into the blood likely resembles the microRNAs 
exported from the small intestine. This could obscure any microRNA biomarkers present 
in the serum samples. CAG can proceed continuously through dysplasia to develop 
gastric cancer [212]. The study that identified the ten serum microRNA biomarkers for 
this disease did not include every stage in this progression. Instead, patients with CAG 
were compared against patients with a related condition, chronic non-atrophic gastritis 
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[212]. This allowed for a binary decision to occur without ambiguity among the groups 
being compared.  
BE pathogenesis is diagnosed as a step by step progression; however, it is a continuous 
process. Although BE pathogenesis is separated into four pathology groups for this study, 
the groups are not well delineated. The pathology groups do not describe how close each 
patient was to entering the next stage of BE pathogenesis. BE is often not diagnosed 
immediately upon formation of the lesions, and it is impossible to predict when each 
patient will begin the transition to the next stage. Thus, using serum microRNAs to 
cluster patients into four groups based on pathology was not successful in this study.  
It was expected that, of the four pathology groups, EAC would have yielded significantly 
differently expressed serum microRNAs. In the GSA, miR-194-5p was significantly 
downregulated in EAC vs BE tissues. Eight microRNAs known to be differently 
regulated in various cancers were included in the top twenty most important microRNAs 
for the serum randomForest classification, randomForest regression, or both analyses 
(Figures 10 and 11). None of these eight microRNAs were significantly differentially 
expressed in any comparison in the GSA. 
Serum is not the only biofluid available for non-invasive diagnosis of BE pathogenesis. 
Four differentially expressed microRNAs have been detected in saliva of esophageal 
cancer patients [213]. Three of these microRNAs, miR-144, miR-21-3p, and miR-451a, 
showed similar, if not statistically significant, fold changes in the tissue of EAC patients 
when compared to BE patients in this study. However, these trends were not observed in 
the serum of EAC patients when compared to BE patients.  
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Despite the limitations imposed by the biology of BE pathogenesis, serum microRNA 
biomarkers for this disease may still be revealed if the technical limitations of this study 
are addressed. This study was unique in that four stages of BE pathogenesis were 
examined in serum samples. Five studies have identified serum microRNA biomarkers 
for BE or EAC when compared against controls [129, 130, 214-216]. All these studies 
utilized either qPCR on select microRNAs or microRNA qPCR arrays to detect 
differential expression of serum microRNAs. In this study, qPCR was reserved for 
validation of those serum microRNAs discovered by small RNA-seq.  
For the serum cDNA libraries, small RNAs were extracted from 600ul serum for each 
patient using the mirVana Paris RNA and Protein Isolation kit. The five previous studies 
were able to extract enough microRNAs from 200-900ul serum for detection of 
differential expression by qPCR [129, 130, 214-216]. In this study, the microRNA 
concentration for each patient serum sample following small RNA extraction was 
unknown. It is possible that extraction from 600ul serum simply did not provide enough 
starting microRNA material for optimal small RNA-seq results. A kit optimized for 
extraction of exosomes from serum samples may be more suited for this type of study.  
The threshold chosen for the quality control step following small RNA-seq was 200,000 
microRNA reads, as assessed by the Ion Torrent smallRNA_analysis plugin. This 
threshold was selected in order to increase the number of tissue and serum samples 
included in each pathology group for data analysis. However, a 200,000 microRNA reads 
threshold may have been too low and allowed for numerous Type II statistical errors. If 
the cDNA libraries each had possessed 1 million or more microRNA reads to increase 
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statistical power, more significantly differentially expressed serum microRNAs may have 
been revealed.  
Tissue 
Six microRNAs were found to be differentially expressed in BE pathogenesis (Table 6). 
Of these six, only two microRNAs, miR-596 and miR-4655-3p, were novel. In previous 
studies, over 90 microRNAs have been found to be differentially expressed in BE and 
EAC tissues [94]. While not all 90 microRNAs passed the Bonferroni threshold and thus 
were not considered statistically significant, many serum and tissues still appeared to be 
differentially regulated in this study in the same manner as in literature (Table 11). In this 
study, only three of the 90 microRNAs appeared as significantly differentially expressed 
in the fresh-frozen patient tissues (Table 11). This may be due to small sample size; only 
5-8 patients were available for each pathology group. This small sample number perhaps
could not overcome the variability within the pathology groups caused by the 
heterogeneity inherent to BE and its associated dysplasia and EAC.  
To identify differential expression of microRNAs in BE pathogenesis, previous studies 
have employed targeted experimental techniques such as microarrays and qPCR [94]. 
Prior to this study, next generation sequencing techniques, which capture global 
microRNA expression, had been utilized in three studies for BE pathogenesis [217-219]. 
Expression fold changes for tissue microRNAs identified in these studies generally match 
the direction of differential expression observed in this study for comparisons between 
BE and GERD and EAC and GERD. 
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Table 11: Serum and Tissue microRNAs Differentially Expressed in BE Literature 
Serum Tissue 
microRNA1 Adjusted p-value3 Fold Change Adjusted p-value3 Fold Change 
miR-196a-5p2,4 2.58E-04 1.87 2.70E-07 18.31 
miR-3613-5p2 4.99E-03 1.49 1.83E-03 1.21 
miR-375 --- --- 3.03E-03 1.03 
miR-135b-3p --- --- 1.85E-03 1.33 
miR-192-5p --- --- 2.85E-04 2.06 
miR-194-5p4 --- --- 1.39E-04 2.67 
miR-196b-5p4 --- --- 1.77E-06 23.19 
miR-199a-5p --- --- 2.91E-03 1.04 
miR-215-3p4 --- --- 2.13E-04 37.88 
miR-542-3p --- --- 1.25E-03 2.04 
miR-136-3p 2.41E-03 1.43 --- --- 
miR-29c-3p 4.55E-03 1.08 --- --- 
miR-30a-3p 2.01E-03 2.04 --- --- 
miR-376c-3p 2.34E-03 1.41 --- --- 
miR-409-3p 7.24E-05 3.39 --- --- 
miR-501-5p 8.62E-04 1.69 --- --- 
miR-551b-3p 2.12E-03 1.17 --- --- 
miR-133a-3p2 1.39E-03 -1.09 1.85E-03 -1.35
miR-33a-3p2 3.37E-03 -1.18 1.18E-03 -1.64
miR-99a-3p2 2.50E-03 -1.43 5.96E-04 -2.31
miR-543 --- --- 3.09E-03 -1.43
miR-4462 --- --- 5.83E-04 -1.65
miR-125b-2-3p --- --- 3.39E-03 -1.65
miR-127-3p --- --- 1.73E-03 -1.37
miR-133b --- --- 2.38E-03 -1.03
miR-136-5p --- --- 7.77E-04 -1.73
miR-149-5p --- --- 2.29E-04 -3.93
miR-154-5p --- --- 8.39E-04 -2.02
miR-205-5p --- --- 6.14E-05 -12.27
miR-224-5p --- --- 1.23E-03 -3.60
miR-382-5p --- --- 1.89E-03 -1.66
miR-708-5p --- --- 6.39E-04 -2.53
miR-10a-5p 2.71E-04 -2.26 --- ---
miR-1-3p 1.82E-04 -3.35 --- ---
miR-18a-3p 3.56E-03 -1.02 --- ---
1Show similar trends in expression levels in BE literature and in BE vs GERD 
comparison from small RNA-seq 
2Differentially Expressed in both Serum and Tissue data sets from small RNA-seq 
3p-values Bonferroni-corrected for multiple comparisons.
4 Determined to be significantly differentially expressed after Bonferroni correction 
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As previously discussed, BE pathogenesis is continuous, rather than consisting of discrete 
stages. Perhaps if 1 million or more microRNA reads for each library had been obtained 
or if more samples per pathology group had been collected, the biological limitations to 
this study could have been surmounted.  
HOX microRNAs may regulate posterior HOX genes as part of a Negative 
Feedback Mechanism 
Two of the candidate tissue microRNAs from this study, miR-196a-5p and miR-196b-5p, 
are considered HOX microRNAs, as they are transcribed from genes intergenic to HOX 
genes [220]. HOX genes are homeotic genes, a set of transcription factors that contain a 
DNA-binding homeobox domain. These genes are responsible for gene expression 
patterning along the AP axis and as such are essential for establishing and maintaining 
the identities of the foregut, midgut, and hindgut in embryonic development [74]. In the 
human, thirty-nine HOX genes are divided into four gene clusters, the results of past 
genome duplications [80]. In the A, B, C, and D clusters, the HOX genes are organized 
on the chromosome in order of their expression on the AP axis (Figure 16). Correct HOX 
gene function is dependent on the place and time of its expression. Generally, the HOX 
genes are grouped into three groups: anterior, central, and posterior (Figure 16) [71, 72]. 
Central HOX genes from the HOXB cluster have been found to be upregulated in BE 
tissues [69]. No studies to date have examined the differential expression of microRNAs 
and their regulation of HOX genes in BE pathogenesis. 
Five HOX microRNAs can be transcribed from within the human HOX clusters [220]. 
miR-10a-5p, miR-10b-5p, and miR-615-3p can be transcribed from genes intergenic to 
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Figure 16: Collinear Expression of HOX genes on the Anterior/Posterior (AP) Axis 
Four HOX gene clusters in humans are a result of multiple genome duplications. Thirty-
nine HOX genes are divided across these clusters. Not all HOX clusters contain all 13 
gene homologs. Genes are grouped into three general categories: anterior (HOX1-3), 
central (HOX4-8), and posterior (HOX 9-13). These categories define the positional 
expression for those HOX genes. Arrows denote locations of genes encoding HOX 
microRNAs: (A) MIR-196b encodes miR-196b-5p. (B) MIR-196a-1 encodes miR-196a-
5p. (C) MIR-196a-2 encodes miR-196a-5p (D) MIR-10a encodes miR-10a-5p (E) MIR-
10b encodes miR-10b-5p (F) MIR-615 encodes miR-615-3p.  
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anterior HOXA, HOXD, and HOXC genes, respectively (Figure 16) [220]. In this study, 
these three microRNAs all displayed increased expression in the BE vs GERD 
comparison for the tissue dataset. However, the differential expression did not pass the 
Bonferroni threshold and therefore was not considered statistically significant. miR-10a-
5p and miR-10b-5p are among the twenty most important microRNAs in the tissue 
randomForest classification analysis (Figure 10). miR-10a-5p and miR-615-3p are among 
the twenty most important microRNAs in the tissue randomForest regression analysis 
(Figure 11).  
miR-196a-5p can be transcribed from genes intergenic to either posterior HOXB or 
HOXC genes, while miR-196b-5p originates from a gene adjacent to HOXA9 [220]. 
HOX microRNAs are often co-expressed with adjacent HOX genes. Both microRNAs 
had significantly increased expression in BE tissues when compared to GERD tissues in 
this study. In Huntington’s Disease, miR-196a-5p upregulation has been correlated with 
increased transcription of HOXC10 or HOXB9, while upregulation of HOXA10, 
HOXA11, or HOXA13 have been associated with increased expression of miR-196b-5p 
[186]. In this study, the comparative upregulation of these two microRNAs in the BE 
patients may indicate an initial increase in central and posterior HOX gene expression in 
BE development (Figure 17).  
Gene target analysis for miR-196a-5p and miR-196b-5p demonstrated regulation of 
central and posterior HOX genes from the HOXA, HOXB, and HOXC clusters (Table 
10). This may be evidence of a negative feedback mechanism where posterior HOX 
genes are targeted by co-expressed HOX microRNAs (Figure 17).  
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Figure 17: A Model for Homeotic Gene Regulation in BE Development 
In BE development, increased expression of miR-196a-5p, miR-196b-5p, and miR-215-
3p may indicate a mechanism for fine tuning posterior HOX gene expression in the distal 
esophagus. miR-196a-5p and miR-196b-5p can both be transcribed from genes adjacent 
to posterior HOX genes. miR-196b-5p and miR-196a-5p are transcribed from genes 
intergenic to the HOXA and HOXB and HOXC clusters. Their co-expression with 
posterior HOX genes allows for their targeting of central and posterior genes in the other 
HOX gene clusters, a negative feedback mechanism. miR-196b-5p is also known to 
target MEIS1, a HOX co-factor. MLL complex activates HOX genes by methylation of 
histone 3 at Lysine 4 (H3K4me) and opening chromatin structure. MLL complex can also 
methylate histone3 at Lysine 79 (H3K79me) at MIR-196b in the HOXA cluster, leading 
to miR-196b-5p expression. CDX1 can bind to HOX gene promoters to activate HOX 
gene expression. CDX1 also activates miR-215-3p, allowing this microRNA to target 
BMI1, a component of PRC1. PRC1 and PRC2 work in conjunction to trimethylate 
histone 3 at Lysine 27 (H3K27me3) and compact chromatin structure. Thus, posterior 
HOX genes may be aberrantly expressed in BE pathogenesis under indirect and direct 
regulation by the candidate microRNAs of this study. 
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miR-215-3p and miR-196b-5p are involved in indirect regulation of HOX gene 
expression 
In humans, polycomb repressive complexes (PRC) and complexes of Mixed Lineage 
Leukemia (MLL) proteins work in opposition to regulate HOX gene expression [81, 84]. 
PRC2 and PRC1 act in conjunction to repress HOX gene expression through methylation 
of histone H3 at Lysine 27 (H3K27me) and compaction of chromatin structure, 
respectively [221]. Transcription machinery access to HOX genes located in PRC1-
catalyzed compacted chromatin would be restricted [222]. Thus, PRC1 can repress 
central or posterior HOX gene expression in anterior regions of the body. MLL is a 
histone methyltransferase that binds to promoters of HOX genes and methylates histone 
H3 at Lysine 4 (H3K4me) to activate HOX gene expression [81]. The H3K4me 
epigenetic mark can recruit chromatin remodeling factors which open chromatin and 
allow active transcription [223].  
miR-215-3p targets BMI1, a component of PRC1 
PRC2 trimethylates histone H3 at Lysine 27, a signal which recruits PRC1 through one of 
its core components, BMI1 [224]. The exact mechanism behind PRC1’s ability to 
compact chromatin is still unclear. BMI1 is required for PRC1-catalyzed chromatin 
compaction and subsequent gene silencing [225].  BMI1 is an experimentally-validated 
target of miR-215-3p [189]. Expression of posterior HOXB genes in BE tissues was 
associated with loss of the H3K27 methylation and decompaction of chromatin at the 5’ 
end of the HOXB gene cluster [69]. This would suggest that PCR1 repression of central 
and posterior HOXB genes in the distal esophagus is released in BE development.  
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CDX1 has been shown to promote expression of miR-215-3p (Figure 17) [189]. CDX 
genes, including CDX1, are known regulators of HOX genes [39]. CDX gene mutations 
in humans can lead to homeotic transformations in the central regions of the body due to 
dysregulation of posterior HOX genes [47]. CDX binding sites have been found in 
enhancer elements of HOX genes, where CDX genes are thought to acetylate H3K27 to 
activate central HOX genes [93]. CDX1 expression in the distal esophagus may precede 
central and posterior HOX gene expression in BE.  
Multiple Lineage Leukemia (MLL) Complex promotes mir-196b-5p expression 
MLL1 is a human homolog to Trithorax originally identified in Drosophila [226]. In 
embryonic development, MLL1 works in a complex with other MLL proteins to 
upregulate central and posterior HOX genes in the posterior segments of the body [82]. 
MLL complexes directly bind to HOX promoters to apply an activating epigenetic 
marker, H3K4 trimethylation [81] [84, 227, 228]. The presence of H3K4me3 recruits the 
transcription factor TFIID, an initiating player in gene transcription [228-230].  No study 
to date has examined differential expression of MLL in the human esophagus.  
MLL complex has been shown to promote miR-196b-5p expression [231]. This complex 
methylates Lysine 79 on histone H3 (H3K79me) in certain regions of the HOXA cluster 
[231]. This epigenetic modification is associated with transcription activation [232]. One 
region that is affected by this modification contains MIR-196b, the gene which encodes 
miR-196b-5p. The observed increased expression of miR-196b-5p in the BE patient 
tissues in this study may have been due to the action of MLL complex in BE 
development. miR-196b-5p, in turn, can target the HOX cofactor, myeloid ecotropic viral 
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integration site 1 (MEIS1) [233, 234]. MEIS1 is a member of the three amino acid loop 
extension (TALE) homeobox gene cluster, which all encode atypical homeodomains 
[235]. These genes act as cofactors for HOX genes by augmenting their DNA binding, 
thereby enhancing transcriptional regulation by HOX genes [236]. Thus, increased 
expression of miR-196b-5p has a detrimental effect on the activity of HOX genes.  
A Model for Homeotic Gene Regulation in BE Development 
It is unknown what molecular mechanisms contribute to the formation of BE lesions in 
GERD patients. Three candidate microRNAs were identified by small RNA-seq in fresh-
frozen BE patient tissues and validated in FFPE BE tissues by qPCR. Upregulation of 
miR-196a-5p, miR-196b-5p, and miR-215-3p posits a model for direct and indirect 
regulation of central and posterior HOX genes in BE development (Figure 17).  
The upregulation of miR-196a-5p and miR-196b-5p in BE tissues indicates that posterior 
HOX genes are expressed in BE development, as these HOX microRNAs can be co-
expressed with their adjacent HOX genes. Posterior HOX genes may exist in a bivalent 
state in the distal esophagus. Bivalency describes the presence of active (H3K4me) and 
repressive (H3K27me) epigenetic markers in the same gene promoter [237, 238]. This 
allows affected genes to be silenced but be “poised” for activation. The actions of the 
PRC1/2 complexes and the MLL complex may be in balance to keep posterior HOX 
genes in a bivalent state. The onset of BE development, increased expression of miR-
215-3p and other factors may upset this balance. Removal of PRC1 repression of 
posterior HOX genes could be achieved by the observed upregulation of miR-215-3p in 
BE tissues, as this microRNA targets BMI1, a component of PRC1. miR-215-3p is 
111 
upregulated by CDX1, a well-known biomarker of BE lesions and regulator of central 
and posterior HOX genes[39, 93, 189]. This would allow for co-expression of miR-196a-
5p, miR-196b-5p and their respective adjacent HOX genes. MLL complex can promote 
expression of miR-196b-5p as well [231, 233]. miR-196a-5p and miR-196b-5p are then 
able to target central and posterior HOX gene expression and activity [220, 233]. 
Increased expression of miR-196a-5p, miR-196b-5p, and miR-215-3p in BE development 
may allow for fine-tuning of central and posterior HOX gene expression in the distal 
esophageal epithelium (Figure 17). To test this model, modulation of HOX gene and 
microRNA expression in an experimental construct of BE development would need to be 
assessed. Unfortunately, a technical limitation that has impeded the understanding of BE 
pathogenesis is the lack of an adequate experimental model of BE. Human esophagus is 
lined with a non-keratinized squamous epithelium with submucosal glands. Mice and 
rats, commonly utilized model organisms, have keratinized-lined esophagi which lack 
submucosal glands [239]. It is known that BE can occur in the ducts of the esophageal 
submucosal glands, termed ductal metaplasia or buried BE [240]. This ductal metaplasia, 
like BE, is capable of dysplasia and can produce EAC [241]. The position of the 
gastroesophageal junction is also of import in BE development, as BE is confined to the 
distal esophagus. In mice, induced BE-like lesions can occur in the esophagus and 
proximal stomach, because this junction is positioned further down the GI tract[239]. 
However, the most important factor which separates humans from commonly used 
animal models is that gastroesophageal reflux is a natural occurrence. In other non-
primate mammals, including mice, dogs, and pigs, reflux must be surgically induced in 
order for BE-like lesions to develop [239]. Due to the lack of a practical and biologically 
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relevant animal model, cell lines can be utilized to explore BE development in vitro. 
However, since BE is a metaplasia consisting of both columnar epithelia and intestinal-
type cells, molecular signaling in a single esophageal cell line does not necessarily reflect 
the molecular signaling in the tissue. One technique to address the limitations of a single 
2-D cell line has been a co-culture of multiple esophageal epithelial cell lines in a
collagen matrix [242]. Though this 3-D culture system better approximates the BE 
physiology, it did not include the intestinal-type cells characteristic of BE. There is a 
distinct need for a model system derived from human esophageal tissue which can be 
cultured and maintained long-term, while still reflecting all the hallmarks of the BE 
phenotype. 
If an appropriate experimental construct of BE development can be identified, 
modulation of central and posterior HOX gene transcription and translation would need 
to be explored. While qPCR is a standard assay technique for gene transcription, an array 
of techniques could be utilized to assay for HOX protein expression. In their 2012 study, 
Di Pietro et al utilized in situ hybridization and western blots to probe for HOX gene 
expression in BE tissues [69]. To further verify that the three candidate microRNAs 
target central and posterior HOX genes, BMI1, and MEIS1, a biotin-based pull-down 
assay may be utilized [243]. This method has been shown to be more specific than other 
techniques to validate microRNA targets, such as microRNA overexpression experiments 
[244]. microRNAs can block association of an mRNA with ribosomes to block 
translation, thus polyribosome (polysome) fractionation analysis can determine the 
strength of microRNA targeting [245, 246].  
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The model presented in Figure 17 is only possible through modulation of chromatin 
structure enacted through histone modifications by PRC1 and MLL complexes. 
Chromatin Immunoprecipitation (ChIP) can be utilized to assess methylation and 
acetylation at Lysines 27 and 79 on histone H3 at HOX gene promoters [247]. This 
technique could also validate binding of MLL1 and CDX1 to intergenic regions of central 
and posterior HOX genes.  
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12 9 5pM 11% 26,165,642 58% 24% 
2 8 5pM 11% 33,467,142 61% 14% 
3 13 5pM 10% 24,327,612 76% 16% 
4 13 7.5pM 10% 24,983,549 78% 12% 
53 4 5pM 29% 17,460,404 16% 28% 
6 5 5pM 8% 23,737,059 71% 26% 
7 5 5pM 8% 12,794,097 70% 24% 
8 5 15pM 13% 25,780,881 74% 16% 
9 7 15pM 19% 42,018,947 62% 17% 
10 7 15pM 15% 28,952,314 77% 12% 
11 6 20pM 32% 35,833,666 65% 20% 
12 9 15pM 21% 36,567,578 66% 21% 
13 6 15pM 28% 46,417,922 53% 25% 
14 10 15pM 19% 38,863,719 48% 24% 
15 9 15pM 28% 43,534,071 61% 16% 
16 14 15pM 23% 45,600,035 55% 25% 
1 ISP: Ion SphereTM Particles 
2 Inefficient loading of the Ion PI chip affected total and microRNA reads. Samples 
were rerun   on Chip 2 
3Inefficient loading of the Ion PI chip affected total reads but not microRNA reads. 
Small RNA control from kit was included.  
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1S BE 148.6 28 2 1,165,368 --- --- 
1T BE 82.8 51 7 409,317 --- --- 
2S GERD 123.2 49.2 3 493,212 --- --- 
2T GERD 115.2 66.8 14 587,689 --- --- 
3S GERD 34.8 10 1 --- --- --- 
3S GERD 95 18.05 1 --- --- --- 
3S GERD 81.8 26.5 1 857,667 --- --- 
3T GERD 205.2 71 9 --- --- --- 
3T GERD 178.15 72.45 8 65,358 --- --- 
4S Normal 365.5 2.36 7 2,058,239 --- --- 
4T Normal 46.9 22.7 1 --- --- --- 
4T Normal 160.4 94.9 1 820,424 --- --- 
5S GERD 95.7 11.1 11 --- --- --- 
5S GERD 160.1 23.9 12 --- --- --- 
5T GERD No library made --- --- --- --- --- 
6S GERD 257.9 186.9 8 67,564 65,239 45,648 
6S GERD 117.6 70.6 14 39,076 24,837 --- 
6T GERD 87.5 59.3 2 1,538,959 675,776 619,922 
7S GERD 425.30 275.1 9 3,939,615 --- --- 
7T GERD 41.3 29.9 3 67,000 50,000 --- 
8S GERD Not received --- --- --- --- --- 
8T GERD Not received --- --- --- --- --- 
9S Normal 205.2 131.35 15 52,955 20,425 20,294 
9S Normal 283.6 62.3 10 259,675 --- --- 
9T Normal 109 76.2 4 403,891 --- --- 
9T Normal 20.5 18.8 4 478,133 --- --- 
10S GERD Not received --- --- --- --- --- 
10T GERD Not received --- --- --- --- --- 
11S BE 259.35 158.25 16 --- --- --- 
11S BE 315 173 10 24,928 --- --- 
11T BE 166.8 59.7 6 89,451 --- --- 
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12S LGD 122.9 0.7 9 --- --- --- 
12S LGD 40.3 18.6 15 47,583 --- --- 
12T LGD 99.1 71.7 12 157,235 --- --- 
13S EAC 334.2 226.6 11 267,217 162,316 77,946 
13T EAC 135.2 98.85 5 84,000 40,000 31,000 
13T EAC 214.9 150.4 5 336,937 --- --- 
13T EAC 241.1 153 1 733,000 --- --- 
14S GERD 10.3 2.05 13 --- --- --- 
14T GERD Not received --- --- --- --- --- 
15S BE 227.5 130.7 12 565,053 367,094 65,239 
15T BE 24.2 9.1 6 --- --- --- 
15T BE 63.5 42.3 6 130,000 105,000 --- 
15T BE 247.6 174.6 4 454,000 --- --- 
16S1 LGD 87.8 33.7 13 225,876 110,003 --- 
16T LGD 128.85 70.1 7 373,289 303,889 --- 
16T1 LGD 28 12 5 171,798 --- --- 
16T LGD 15.2 11.1 7 269,103 --- --- 
17S LGD 71.3 19.2 1 --- --- --- 
17S1 LGD 368.8 151.7 1 261,515 --- --- 
17S LGD 165 110.8 1 --- --- --- 
17T LGD 41.2 28.15 7 --- --- --- 
17T LGD 331.9 215.7 2 1,494,000 --- --- 
18S BE 48.1 27.8 2 -- --- --- 
18S BE 338.1 162 2 -- --- --- 
18S BE 244 183.6 2 844,152 --- --- 
18T BE 120.05 91.35 8 119,000 76,000 62,000 
18T BE 120.05 91.35 8 37,997 --- --- 
19S1 GERD 67.1 15.9 3 121,174 --- --- 
19S GERD 374.3 196.3 3 195,120 --- --- 
19S GERD 447 258.1 3 299,691 --- --- 
19T GERD 74.75 60.45 9 123,113 120,310 79,137 
19T GERD 257.4 194.9 6 155,621 --- --- 
20S BE 57.9 24.5 4 --- --- --- 
20S BE 587.2 236.1 4 --- --- --- 
20S BE 79.4 56.1 4 1,620,830 617,535 540,092 
20T BE 166.7 129.1 10 100,000 90,000 79,000 
20T BE 187.7 131.8 10 2,009,572 --- --- 
21S1 GERD 489.2 84.6 5 63,046 --- --- 
21S GERD 366.8 177.9 5 64,190 --- --- 
21S GERD 371.6 225.7 5 2,917,007 --- --- 
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21T1 GERD 92.4 57.9 11 77,965 --- --- 
21T GERD 199.9 157.1 7 403,686 --- --- 
21T GERD 9.6 9 11 103,850 --- --- 
22S BE 53 12.6 6 --- --- --- 
22S BE 376.7 153.6 6 --- --- --- 
22S BE 143.6 52.7 6 --- --- --- 
22S BE 315.3 91.4 6 105,306 --- --- 
22T BE 129.8 92.2 12 60,866 --- --- 
23S GERD 211.2 117.2 13 1,731,449 --- --- 
23T GERD 79.05 51.95 13 240,323 226,658 172,304 
24S BE 219.4 130.1 14 660,978 460,448 --- 
24T BE 64.55 41.15 14 135,218 --- --- 
24T BE 230.5 174.7 8 156,000 --- --- 
25S Normal 56.8 37.5 15 2,056,656 --- --- 
25S Normal 304.2 199.3 15 65,373 --- --- 
25T Normal 123.4 73.6 15 121,540 --- --- 
26S EAC 274.9 148.1 16 221,207 --- --- 
26T EAC 173 132.4 16 130,000 98,000 --- 
26T EAC 215.3 148.9 10 2,762,128 --- --- 
27S EAC 370 276.4 10 201,209 115,318 61,062 
27T EAC 54 32.5 1 --- --- --- 
27T EAC 28.05 17.5 13 --- --- --- 
27T EAC 238.7 172.7 3 575,000 --- --- 
24T BE 64.55 41.15 14 135,218 --- --- 
24T BE 230.5 174.7 8 156,000 --- --- 
25S Normal 56.8 37.5 15 2,056,656 --- --- 
25S Normal 304.2 199.3 15 65,373 --- --- 
25T Normal 123.4 73.6 15 121,540 --- --- 
26S EAC 274.9 148.1 16 221,207 --- --- 
26T EAC 173 132.4 16 130,000 98,000 --- 
26T EAC 215.3 148.9 10 2,762,128 --- --- 
27S EAC 370 276.4 10 201,209 115,318 61,062 
27T EAC 54 32.5 1 --- --- --- 
27T EAC 28.05 17.5 13 --- --- --- 
27T EAC 238.7 172.7 3 575,000 --- --- 
28S LGD 242.45 86.25 2 --- --- --- 
28S LGD 131.4 102.5 2 217,622 130,048 73,585 
28T LGD 80.1 60.2 2 --- --- --- 
28T LGD 272.1 171.1 9 1,664,468 --- --- 
29S BE 90.35 46 3 --- --- --- 
29S BE 455.8 309.5 3 836,870 473,280 --- 
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29T BE 118.1 83.7 3 116, 949 --- --- 
29T BE 37.95 24.95 15 236,985 --- --- 
30S Normal 129.8 65.7 4 --- --- --- 
30S Normal 77.3 31.2 16 754,897 --- --- 
30T Normal 106.3 69.4 4 1,031,683 --- --- 
31S ESCC Library not made --- --- --- 
--- --- 
31T ESCC 64.3 43.5 5 --- --- --- 
32S GERD 231.6 158.8 14 --- --- --- 
32S GERD 136.9 64.2 4 602,971 --- --- 
32T GERD 20.6 8.1 9 --- --- --- 
32T GERD 93.1 49.7 16 1,115,086 --- --- 
33S BE 119.2 57.2 5 910,976 --- --- 
33T BE 120.3 77.5 11 460,777 --- --- 
34S EAC 461.55 229.05 8 247,384 --- --- 
34T EAC 78.05 42.6 8 79,052 --- --- 
34T EAC 409.7 283.8 4 652,918 --- --- 
35S GERD 374 243.7 2 109,889 --- --- 
35T GERD 350.8 259.1 8 --- --- --- 
36S GERD 404.3 235 7 1,670,527 --- --- 
36T GERD 301.8 205 14 101,000 --- --- 
36T GERD 324.7 230.6 1 330,521 --- --- 
37S LGD 494.00 290.45 11 5,969,490 --- --- 
37T LGD 82.45 46.25 11 98,000 --- --- 
37T LGD 82.45 46.25 11 48,000 --- --- 
37T LGD 195 109 5 4,060,390 --- --- 
38S EAC 294.8 116.85 12 --- --- --- 
38S1 EAC 229.8 105.75 12 578,011 58,714 --- 
38T EAC 65.1 45.45 12 23,310 --- --- 
38T EAC 65.1 45.45 12 16,829 --- --- 
38T EAC 158.9 85.4 12 2,705,433 --- --- 
39S LGD 361.88 176.4 13 1,651,601 --- --- 
39S LGD 57.7 41.6 13 --- --- --- 
39T LGD 64.6 45 13 769,308 --- --- 
40S1 Normal 108.4 59.5 6 13,538,600 --- --- 
40T Normal 34.1 17.5 5 2,620,041 --- --- 
1 Library was suboptimal (contained adaptor dimers and/or t-RNA peaks) 
2 MicroRNA reads were provided by Ion Torrent smallRNA_analysis plugin, a quality control step.  
Read counts herein differ from those reported in Table 5 as the Ion Torrent and Partek Flow® 
map raw reads to different versions of miRBase, v20 and v21, respectively. 
3Libraries in bold-type had over 200,000 microRNAs and were included in further analyses 
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Appendix III: Variance of TMM-normalized microRNA reads of Selected microRNAs 
microRNA1 Normal GERD BE LGD EAC 
Serum2
hsa-miR-106b-5p 1.60E+08 4.58E+07 1.04E+07 1.52E+08 6.01E+05 
hsa-miR-15a-5p 4.15E+08 1.91E+08 3.19E+07 1.30E+08 4.79E+06 
hsa-miR-181a-5p 2.07E+07 2.40E+06 1.00E+07 1.05E+07 5.82E+06 
hsa-miR-194-5p 6.01E+04 1.96E+04 4.65E+03 1.31E+04 1.80E+02 
hsa-miR-6131 2.17E+06 2.68E+05 4.41E+06 3.53E+05 7.22E+04 
hsa-miR-92a-3p 7.81E+07 4.36E+07 3.37E+07 3.03E+07 1.21E+06 
hsa-miR-93-5p 3.14E+08 7.50E+06 7.57E+06 6.56E+07 2.10E+06 
Tissue2
hsa-miR-106b-5p 1.75E+06 3.52E+04 3.02E+05 5.15E+05 1.29E+07 
hsa-miR-15a-5p 2.85E+06 1.56E+05 1.57E+05 8.28E+05 2.63E+07 
hsa-miR-181a-5p 1.67E+05 5.56E+03 6.47E+04 1.60E+05 1.32E+05 
hsa-miR-194-5p 1.87E+02 1.61E+05 2.53E+05 1.84E+06 4.74E+06 
hsa-miR-6131 4.83E+02 9.79E+02 1.76E+03 1.01E+04 2.31E+04 
hsa-miR-92a-3p 2.97E+05 2.73E+03 2.91E+03 4.20E+04 8.76E+05 
hsa-miR-93-5p 3.09E+06 7.44E+04 1.45E+04 2.03E+05 4.93E+06 
1 Selected microRNAs were chosen based on a GSA performed on serum or tissue 
datasets composed of the same 24 patients (unshown). These microRNAs were unique to 
a specific pair-wise comparison between two of the five patient groups. 
2TMM-normalized microRNA reads from those 24 patients for which both serum and 
tissue samples passed the 200,000 microRNA read count threshold 
3Instances when variance in the Normal patient group exceeded variance in other patient 
groups are in boldtype 
